Cat. No.: HY-B0011A

Docetaxel Trihydrate

Name: Docetaxel Trihydrate
Brand: MedChemExpress
SKU: HY-B0011A
Price: 55.00 USD
Availability: InStock
Rating: 5 (183 reviews)

(Synonyms: RP-56976 Trihydrate)

183 Cited Publications

Avis client

Based on 183 publication(s) in Google Scholar

Docetaxel Trihydrate (RP-56976 Trihydrate) is an orally active tubulin stabilizer with antitumor activity. Docetaxel Trihydrate is a P-glycoprotein substrate and is metabolized by CYP3A to inactive products. Docetaxel Trihydrate binds tubulin, promotes tubulin polymerization, and inhibits microtubule depolymerization. Docetaxel Trihydrate induces aberrant mitosis followed by necrotic-like cell death at low concentrations, and induces G2/M mitotic arrest and drives apoptosis at high concentrations. Docetaxel Trihydrate induces renal injury/renal alterations, sex-dependent granule toxicity/uptake, low cardiac delivery, and decreased hepatic SOD/increased catalase/hepatotoxicity. Docetaxel Trihydrate can be used in cancer-related research.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté : 99.91%
CAS No.: 148408-66-6
Formule: C₄₃H₅₉NO₁₇
Masse moléculaire:861.93

Stockage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Docetaxel Trihydrate Chemical Structure

CAS No.: 148408-66-6

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (183)
Solvant et solubilité
- In Vitro
- In Vivo
Protocole (11)
Pureté et documentation
Références
Help & FAQs
Classifications
Bioz

Activité biologique

Description

IC₅₀ & Target

^[1]

CYP3A

Voir tous les produits spécifiques à Isoform Cytochrome P450 :

Cellular Effect

Cell Line	Type	Value	Description	References
4T1	IC₅₀	63.4 nM Compound: Docetaxel	Cytotoxicity against mouse triple negative 4T1 cells Cytotoxicity against mouse triple negative 4T1 cells	[PMID: 24890652]
A121	IC₅₀	1.2 nM Compound: docetaxel	Concentration required to inhibit growth of human tumor A121 (ovarian) cell line. Concentration required to inhibit growth of human tumor A121 (ovarian) cell line.	[PMID: 8831755]
A121	IC₅₀	1.2 nM Compound: Docetaxel	Growth inhibition of human ovarian carcinoma (A121) cell line Growth inhibition of human ovarian carcinoma (A121) cell line	[PMID: 9022793]
A121	IC₅₀	1.2 nM Compound: Docetaxel	Inhibition of the growth against human Ovarian Carcinoma (A121) cell line after 72 hr exposure Inhibition of the growth against human Ovarian Carcinoma (A121) cell line after 72 hr exposure	[PMID: 9022794]
A121	IC₅₀	1.2 nM Compound: Docetaxel	Cytotoxicity against human A121 ovarian cells Cytotoxicity against human A121 ovarian cells	10.1016/S0960-894X(01)80298-5
A121	IC₅₀	1.2 nM Compound: Docetaxel	Cytotoxicity was evaluated in vitro against A121 (ovarian carcinoma) human tumor cell lines Cytotoxicity was evaluated in vitro against A121 (ovarian carcinoma) human tumor cell lines	10.1016/S0960-894X(01)80568-0
A121	IC₅₀	1.2 nM Compound: Docetaxal	Cytotoxicity was evaluated against A121 ovarian carcinoma human cancer cell line Cytotoxicity was evaluated against A121 ovarian carcinoma human cancer cell line	10.1016/S0960-894X(96)00595-1
A2780	IC₅₀	0.5 nM Compound: 8	Cytotoxicity against human A2780 cells Cytotoxicity against human A2780 cells	[PMID: 17206139]
A2780	IC₅₀	0.6 nM Compound: 1b	Cytotoxicity against human A2780 cells after 48 hrs by MTT assay Cytotoxicity against human A2780 cells after 48 hrs by MTT assay	[PMID: 19128972]
A2780	IC₅₀	290 nM Compound: 1b	Cytotoxicity against p-glycoprotein expressing drug-resistant human A2780 cells after 48 hrs by MTT assay Cytotoxicity against p-glycoprotein expressing drug-resistant human A2780 cells after 48 hrs by MTT assay	[PMID: 19128972]
A2780	IC₅₀	126 nM Compound: Docetaxel	Antiproliferative against multidrug-resistant human A2780 cells after 72 hrs by MTT assay Antiproliferative against multidrug-resistant human A2780 cells after 72 hrs by MTT assay	[PMID: 24835987]
A2780	IC₅₀	33 nM Compound: Docetaxel	Antiproliferative against human A2780 cells after 72 hrs by MTT assay Antiproliferative against human A2780 cells after 72 hrs by MTT assay	[PMID: 24835987]
A2780	IC₅₀	0.6 nM Compound: Docetaxel	Cytotoxicity against human A2780 cells by MTT assay Cytotoxicity against human A2780 cells by MTT assay	[PMID: 25047938]
A2780	IC₅₀	1 nM Compound: docetaxel	Cytotoxicity against A2780-C25, oxaliplatin-resistant Ovarian carcinoma cell line Cytotoxicity against A2780-C25, oxaliplatin-resistant Ovarian carcinoma cell line	[PMID: 8831755]
A2780	IC₅₀	1.2 nM Compound: docetaxel	Cytotoxicity against A2780-WT, human ovarian carcinoma cell line Cytotoxicity against A2780-WT, human ovarian carcinoma cell line	[PMID: 8831755]
A2780	IC₅₀	1.4 nM Compound: docetaxel	Cytotoxicity against A2780-CP3, cisplatin-resistant Ovarian carcinoma cell line Cytotoxicity against A2780-CP3, cisplatin-resistant Ovarian carcinoma cell line	[PMID: 8831755]
A2780	IC₅₀	122 nM Compound: docetaxel	Cytotoxicity against A2780-DX5, Doxorubicin-resistant Ovarian carcinoma cell line Cytotoxicity against A2780-DX5, Doxorubicin-resistant Ovarian carcinoma cell line	[PMID: 8831755]
A2780	IC₅₀	1.8 nM Compound: taxotere	Concentration of compound to inhibit the growth of human A2780 ovarian carcinoma cells(in vitro) Concentration of compound to inhibit the growth of human A2780 ovarian carcinoma cells(in vitro)	[PMID: 9288161]
A2780 ADR	IC₅₀	285 nM Compound: 8	Cytotoxicity against human A2780AD cells Cytotoxicity against human A2780AD cells	[PMID: 17206139]
A2780 ADR	IC₅₀	290 nM Compound: Docetaxel	Cytotoxicity against human A2780AD cells by MTT assay Cytotoxicity against human A2780AD cells by MTT assay	[PMID: 25047938]
A549	IC₅₀	0.0041 μM Compound: 1b (Docetaxel)	Inhibitory activity against A549 lung cancer cell line Inhibitory activity against A549 lung cancer cell line	[PMID: 12031338]
A549	IC₅₀	0.098 μM Compound: 1b (Docetaxel)	Inhibitory activity against Taxol-resistant A549 lung cancer cell line Inhibitory activity against Taxol-resistant A549 lung cancer cell line	[PMID: 12031338]
A549	IC₅₀	1 nM Compound: Docetaxel	In vitro cytotoxicity of compound against human A549 (non small cell lung) cancer cell line after 72 hr of drug exposure In vitro cytotoxicity of compound against human A549 (non small cell lung) cancer cell line after 72 hr of drug exposure	[PMID: 12477344]
A549	IC₅₀	1 nM Compound: 1b Docetaxel	Compound was tested for its cytotoxicity by inhibiting the growth of A-549 cell line after 72 h Compound was tested for its cytotoxicity by inhibiting the growth of A-549 cell line after 72 h	[PMID: 15225730]
A549	IC₅₀	1 μM Compound: 2	inhibitory concentration against the growth of Non-small-cell lung carcinoma A549 cell line after 72 hr of exposure inhibitory concentration against the growth of Non-small-cell lung carcinoma A549 cell line after 72 hr of exposure	[PMID: 15501062]
A549	IC₅₀	7.2 nM Compound: 8	Cytotoxicity against human A549 cells Cytotoxicity against human A549 cells	[PMID: 17206139]
A549	IC₅₀	>1.4 μg/mL Compound: docetaxel	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 17624790]
A549	IC₅₀	1.7 μM Compound: docetaxel	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 18226907]
A549	IC₅₀	4.95 x 10^-4 μM Compound: docetaxel	Cytotoxicity against human A549 cells after 96 hrs by microplate reader assay Cytotoxicity against human A549 cells after 96 hrs by microplate reader assay	[PMID: 19133778]
A549	IC₅₀	0.37 μM Compound: Taxotere	Cytotoxicity against human A549 cells after 72 hrs Cytotoxicity against human A549 cells after 72 hrs	[PMID: 20849074]
A549	IC₅₀	0.0012 μM Compound: Docetaxel	Cytotoxicity against human A549 cells Cytotoxicity against human A549 cells	[PMID: 21470864]
A549	IC₅₀	850 nM Compound: 2, DTX, Taxotere	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 24269481]
A549	IC₅₀	35.2 nM Compound: Docetaxel	Antiproliferative against human A549 cells after 72 hrs by MTT assay Antiproliferative against human A549 cells after 72 hrs by MTT assay	[PMID: 24835987]
A549	IC₅₀	1 nM Compound: docetaxel	Concentration required to inhibit growth of human tumor A549 (NSCL) cell line. Concentration required to inhibit growth of human tumor A549 (NSCL) cell line.	[PMID: 8831755]
A549	IC₅₀	1 nM Compound: Docetaxel	Growth inhibition of human non-small-lung carcinoma (A549) cell line Growth inhibition of human non-small-lung carcinoma (A549) cell line	[PMID: 9022793]
A549	IC₅₀	1 nM Compound: Docetaxel	Inhibition of the growth against human non-small-lung carcinoma (A549) cell line after 72 hr exposure Inhibition of the growth against human non-small-lung carcinoma (A549) cell line after 72 hr exposure	[PMID: 9022794]
A549	IC₅₀	27.256 μg/mL Compound: Docetaxel	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	10.1007/s00044-013-0582-8
A549	IC₅₀	1 nM Compound: Docetaxel	Cytotoxicity against human A549 non small cell lung cell lines Cytotoxicity against human A549 non small cell lung cell lines	10.1016/S0960-894X(01)80298-5
A549	IC₅₀	1 nM Compound: Docetaxel	Cytotoxicity was evaluated in vitro against A549 (non-small cell lung carcinoma) human tumor cell lines Cytotoxicity was evaluated in vitro against A549 (non-small cell lung carcinoma) human tumor cell lines	10.1016/S0960-894X(01)80568-0
A549	IC₅₀	1 nM Compound: Docetaxal	Cytotoxicity was evaluated against A549 non-small cell lung carcinoma human cancer cell line Cytotoxicity was evaluated against A549 non-small cell lung carcinoma human cancer cell line	10.1016/S0960-894X(96)00595-1
B16	ED₅₀	11 μM Compound: 2 (docetaxel)	The compound was tested for Cytotoxic concentration against B16 melanoma cells. The compound was tested for Cytotoxic concentration against B16 melanoma cells.	[PMID: 7562913]
B16	ED₅₀	27 μM Compound: 2 (docetaxel)	The compound was tested for Cytotoxic concentration against B16 melanoma cells relative to paclitaxel The compound was tested for Cytotoxic concentration against B16 melanoma cells relative to paclitaxel	[PMID: 7562913]
Bel-7402	IC₅₀	1.9 nM Compound: Docetaxel	Antiproliferative activity against human Bel7402 after 72 hrs by CellTiter Glo assay Antiproliferative activity against human Bel7402 after 72 hrs by CellTiter Glo assay	[PMID: 22320354]
C6	IC₅₀	1 nM Compound: docetaxel	Cytotoxicity against Pgp deficient human LCC6 cells after 72 hrs by sulforhodamine B test Cytotoxicity against Pgp deficient human LCC6 cells after 72 hrs by sulforhodamine B test	[PMID: 18465846]
Calu-3	IC₅₀	0.1 μM Compound: docetaxel	Cytotoxicity against human Calu3 cells after 72 hrs by SRB assay Cytotoxicity against human Calu3 cells after 72 hrs by SRB assay	[PMID: 19028425]
Cancer cell lines	IC₅₀	1.7 nM Compound: 2 (docetaxel)	Inhibitory concentration required against MKN1 human stomach cancer cell line was determined Inhibitory concentration required against MKN1 human stomach cancer cell line was determined	[PMID: 10397492]
Cancer cell lines	IC₅₀	4.8 nM Compound: 2 (docetaxel)	Inhibitory concentration required against Colon320 human colon cancer cell line was determined Inhibitory concentration required against Colon320 human colon cancer cell line was determined	[PMID: 10397492]
COLO 205	IC₅₀	30.706 μg/mL Compound: Docetaxel	Cytotoxicity against human COLO205 cells after 72 hrs by MTT assay Cytotoxicity against human COLO205 cells after 72 hrs by MTT assay	10.1007/s00044-013-0582-8
ECa-109 cell line	IC₅₀	2.6 μM Compound: docetaxel	Cytotoxicity against human Eca109 cells Cytotoxicity against human Eca109 cells	[PMID: 18701281]
HCC1806	IC₅₀	8.4 μM Compound: docetaxel	Cytotoxicity against human HCC1806 cells after 48 hrs by MTT assay Cytotoxicity against human HCC1806 cells after 48 hrs by MTT assay	[PMID: 22560315]
HCT-116	IC₅₀	0.0022 μM Compound: 1b	Concentration required for inhibition of 50% human colon HCT 116 cell line proliferation after 72 hr of incubation Concentration required for inhibition of 50% human colon HCT 116 cell line proliferation after 72 hr of incubation	[PMID: 15537348]
HCT-116	IC₅₀	0.004 μM Compound: docetaxel	Cytotoxicity against human HCT116 cells Cytotoxicity against human HCT116 cells	[PMID: 15921419]
HCT-116	IC₅₀	0.18 nM Compound: 7	Antiproliferative activity against IC95 biaryl selected drug-resistant against human HCT116 cells after 72 hrs by Cell titer Glo assay Antiproliferative activity against IC95 biaryl selected drug-resistant against human HCT116 cells after 72 hrs by Cell titer Glo assay	[PMID: 17922005]
HCT-116	IC₅₀	0.2 nM Compound: 7	Antiproliferative activity against IC50 biaryl selected human HCT116 cells expressing Kinesin-like protein KIF11 D130V mutant after 72 hrs by Cell titer Glo assay Antiproliferative activity against IC50 biaryl selected human HCT116 cells expressing Kinesin-like protein KIF11 D130V mutant after 72 hrs by Cell titer Glo assay	[PMID: 17922005]
HCT-116	IC₅₀	0.23 nM Compound: 7	Antiproliferative activity against human HCT116 cells expressing Kinesin-like protein KIF11 D130V mutant after 72 hrs by Cell titer Glo assay Antiproliferative activity against human HCT116 cells expressing Kinesin-like protein KIF11 D130V mutant after 72 hrs by Cell titer Glo assay	[PMID: 17922005]
HCT-116	IC₅₀	0.3 nM Compound: 7	Antiproliferative activity against human HCT116 cells after 72 hrs by Cell titer Glo assay Antiproliferative activity against human HCT116 cells after 72 hrs by Cell titer Glo assay	[PMID: 17922005]
HCT-116	IC₅₀	0.31 nM Compound: 7	Antiproliferative activity against IC50 biaryl selected drug-resistant against human HCT116 cells after 72 hrs by Cell titer Glo assay Antiproliferative activity against IC50 biaryl selected drug-resistant against human HCT116 cells after 72 hrs by Cell titer Glo assay	[PMID: 17922005]
HCT-116	IC₅₀	0.35 nM Compound: 7	Antiproliferative activity against 3x IC95 biaryl selected human HCT116 cells expressing Kinesin-like protein KIF11 D130V mutant after 72 hrs by Cell titer Glo assay Antiproliferative activity against 3x IC95 biaryl selected human HCT116 cells expressing Kinesin-like protein KIF11 D130V mutant after 72 hrs by Cell titer Glo assay	[PMID: 17922005]
HCT-116	IC₅₀	0.59 nM Compound: 7	Antiproliferative activity against IC95 biaryl selected human HCT116 cells expressing Kinesin-like protein KIF11 D130V mutant after 72 hrs by Cell titer Glo assay Antiproliferative activity against IC95 biaryl selected human HCT116 cells expressing Kinesin-like protein KIF11 D130V mutant after 72 hrs by Cell titer Glo assay	[PMID: 17922005]
HCT-116	IC₅₀	8.7 nM Compound: 7	Antiproliferative activity against 3x IC95 biaryl selected drug-resistant against human HCT116 cells after 72 hrs by Cell titer Glo assay Antiproliferative activity against 3x IC95 biaryl selected drug-resistant against human HCT116 cells after 72 hrs by Cell titer Glo assay	[PMID: 17922005]
HCT-116	IC₅₀	1.2 nM Compound: taxotere	Cytotoxicity against human HCT116 cells Cytotoxicity against human HCT116 cells	[PMID: 19572612]
HCT-116	IC₅₀	0.5 nM Compound: docetaxel	Cytotoxicity against human HCT116 cells after 72 hrs by MTS assay Cytotoxicity against human HCT116 cells after 72 hrs by MTS assay	[PMID: 19655762]
HCT-116	IC₅₀	1.2 μM Compound: Taxotere	Cytotoxicity against human HCT116 cells Cytotoxicity against human HCT116 cells	[PMID: 20481544]
HCT-116	IC₅₀	0.52 nM Compound: Taxotere	Cytotoxicity against human HCT116 cells after 72 hrs by MTS assay Cytotoxicity against human HCT116 cells after 72 hrs by MTS assay	[PMID: 21142180]
HCT-116	IC₅₀	0.52 nM Compound: taxotere	Cytotoxicity against human HCT116 cells incubated for 72 hrs by MTS assay Cytotoxicity against human HCT116 cells incubated for 72 hrs by MTS assay	[PMID: 23072299]
HCT-116	IC₅₀	5 x 10^-8 M Compound: Taxotere	Cytotoxicity against human HCT116 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	[PMID: 23387796]
HCT-116	IC₅₀	5 x 10^-2 μM Compound: Taxotere	Cytotoxicity against human HCT116 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	[PMID: 23387796]
HCT-116	IC₅₀	3 nM Compound: Docetaxel	In vitro inhibition of proliferation of human colon cancer line 116 after 72 hrs incubation. In vitro inhibition of proliferation of human colon cancer line 116 after 72 hrs incubation.	10.1016/S0960-894X(00)80075-X
HCT-15	IC₅₀	13 nM Compound: docetaxel	Cytotoxicity against human HCT15 cells after 72 hrs by MTS assay Cytotoxicity against human HCT15 cells after 72 hrs by MTS assay	[PMID: 19655762]
HCT-8	IC₅₀	3.07 μM Compound: docetaxel	Cytotoxicity against human HCT8 cells Cytotoxicity against human HCT8 cells	[PMID: 18701281]
HEK293	IC₅₀	0.027 μM Compound: 17	Cytotoxicity against HEK293 cells Cytotoxicity against HEK293 cells	[PMID: 17485207]
HeLa	IC₅₀	3.03 μM Compound: docetaxel	Cytotoxicity against human HeLa cells Cytotoxicity against human HeLa cells	[PMID: 18701281]
HeLa	IC₅₀	50.1 nM Compound: Docetaxel	Antiproliferative against human HeLa cells after 72 hrs by MTT assay Antiproliferative against human HeLa cells after 72 hrs by MTT assay	[PMID: 24835987]
Hep 3B2	IC₅₀	38.2 nM Compound: Docetaxel	Antiproliferative activity against human Hep3B after 72 hrs by CellTiter Glo assay Antiproliferative activity against human Hep3B after 72 hrs by CellTiter Glo assay	[PMID: 22320354]
HepG2	IC₅₀	>400 μM Compound: Taxotere	Cytotoxicity against human HepG2 cells by SRB method Cytotoxicity against human HepG2 cells by SRB method	[PMID: 18181575]
HepG2	IC₅₀	>100 nM Compound: Docetaxel	Antiproliferative activity against human HepG2 after 72 hrs by CellTiter Glo assay Antiproliferative activity against human HepG2 after 72 hrs by CellTiter Glo assay	[PMID: 22320354]
HL-60	IC₅₀	0.5 nM Compound: docetaxel	Cytotoxicity against human HL60 cells after 72 hrs by MTS assay Cytotoxicity against human HL60 cells after 72 hrs by MTS assay	[PMID: 19655762]
HL-60	IC₅₀	0.52 μM Compound: Taxotere	Cytotoxicity against human HL60 cells after 72 hrs Cytotoxicity against human HL60 cells after 72 hrs	[PMID: 20849074]
HL-60	IC₅₀	0.5 nM Compound: Taxotere	Cytotoxicity against human HL60 cells after 72 hrs by MTS assay Cytotoxicity against human HL60 cells after 72 hrs by MTS assay	[PMID: 21142180]
HL-60	IC₅₀	531 nM Compound: Taxotere	Cytotoxicity against human HL60R cells after 72 hrs by MTS assay Cytotoxicity against human HL60R cells after 72 hrs by MTS assay	[PMID: 21142180]
HL-60	IC₅₀	0.5 nM Compound: taxotere	Cytotoxicity against human HL60 cells incubated for 72 hrs by MTS assay Cytotoxicity against human HL60 cells incubated for 72 hrs by MTS assay	[PMID: 23072299]
HT-29	IC₅₀	3.34 x 10^-4 μM Compound: docetaxel	Cytotoxicity against human HT-29 cells after 96 hrs by microplate reader assay Cytotoxicity against human HT-29 cells after 96 hrs by microplate reader assay	[PMID: 19133778]
HT-29	IC₅₀	1 nM Compound: docetaxel	Cytotoxicity against human HT-29 cells after 72 hrs Cytotoxicity against human HT-29 cells after 72 hrs	[PMID: 19239240]
HT-29	IC₅₀	0.92 μM Compound: Taxotere	Cytotoxicity against human HT-29 cells after 72 hrs Cytotoxicity against human HT-29 cells after 72 hrs	[PMID: 20849074]
HT-29	IC₅₀	0.00075 μM Compound: Docetaxel	Cytotoxicity against human HT-29 cells Cytotoxicity against human HT-29 cells	[PMID: 21470864]
HT-29	IC₅₀	0.75 nM Compound: Docetaxel	Cytotoxicity against human HT-29 cells Cytotoxicity against human HT-29 cells	[PMID: 21470864]
HT-29	IC₅₀	1.2 nM Compound: docetaxel	Concentration required to inhibit growth of human tumor HT-29 (colon) cell line. Concentration required to inhibit growth of human tumor HT-29 (colon) cell line.	[PMID: 8831755]
HT-29	IC₅₀	1.2 nM Compound: Docetaxel	Growth inhibition of human colon carcinoma (HT-29) cell line Growth inhibition of human colon carcinoma (HT-29) cell line	[PMID: 9022793]
HT-29	IC₅₀	1.2 nM Compound: Docetaxel	Inhibition of the growth against human Colon Carcinoma (HT-29) cell line after 72 hr exposure Inhibition of the growth against human Colon Carcinoma (HT-29) cell line after 72 hr exposure	[PMID: 9022794]
HT-29	IC₅₀	1.2 nM Compound: Docetaxel	Cytotoxicity against human colon HT-29 cell lines Cytotoxicity against human colon HT-29 cell lines	10.1016/S0960-894X(01)80298-5
HT-29	IC₅₀	1.2 nM Compound: Docetaxel	Cytotoxicity was evaluated in vitro against HT-29 (colon carcinoma) human tumor cell lines Cytotoxicity was evaluated in vitro against HT-29 (colon carcinoma) human tumor cell lines	10.1016/S0960-894X(01)80568-0
HT-29	IC₅₀	1.2 nM Compound: Docetaxal	Cytotoxicity was evaluated against HT-29 colon carcinoma human cancer cell line Cytotoxicity was evaluated against HT-29 colon carcinoma human cancer cell line	10.1016/S0960-894X(96)00595-1
Huh-7	IC₅₀	12.1 nM Compound: Docetaxel	Antiproliferative activity against human HuH7 after 72 hrs by CellTiter Glo assay Antiproliferative activity against human HuH7 after 72 hrs by CellTiter Glo assay	[PMID: 22320354]
HUVEC	IC₅₀	56.7 nM Compound: Docetaxel	Cytotoxicity against HUVEC Cytotoxicity against HUVEC	[PMID: 24890652]
IMR-32	IC₅₀	23.71 μg/mL Compound: Docetaxel	Cytotoxicity against human IMR32 cells after 72 hrs by MTT assay Cytotoxicity against human IMR32 cells after 72 hrs by MTT assay	10.1007/s00044-013-0582-8
J774	ED₅₀	0.05 μM Compound: 3a (Taxotere 10-OH)	In vitro cytotoxicity against J774.2 cells after 72 hr incubation. In vitro cytotoxicity against J774.2 cells after 72 hr incubation.	10.1016/S0960-894X(01)80527-8
K562	IC₅₀	6.9 μg/mL Compound: docetaxel	Cytotoxicity against human K562 cells by MTT assay Cytotoxicity against human K562 cells by MTT assay	[PMID: 17624790]
K562	IC₅₀	>400 μM Compound: Taxotere	Cytotoxicity against human K562 cells by SRB method Cytotoxicity against human K562 cells by SRB method	[PMID: 18181575]
K562	IC₅₀	8.5 μM Compound: docetaxel	Cytotoxicity against human K562 cells after 48 hrs by MTT assay Cytotoxicity against human K562 cells after 48 hrs by MTT assay	[PMID: 18226907]
K562	IC₅₀	2.96 μM Compound: docetaxel	Cytotoxicity against human K562 cells Cytotoxicity against human K562 cells	[PMID: 18701281]
KB	IC₅₀	0.0044 μM Compound: 1b (Docetaxel)	Inhibitory activity against KB nasopharynx cancer cell line Inhibitory activity against KB nasopharynx cancer cell line	[PMID: 12031338]
KB	IC₅₀	0.2 μM Compound: 1b (Docetaxel)	Inhibitory activity against Vincristine-resistant KB nasopharynx cancer cell line Inhibitory activity against Vincristine-resistant KB nasopharynx cancer cell line	[PMID: 12031338]
KB	IC₅₀	0.0003 μM Compound: 1b	Concentration required for inhibition of 50% human fibroblast KB cell line proliferation after 72 hr of incubation Concentration required for inhibition of 50% human fibroblast KB cell line proliferation after 72 hr of incubation	[PMID: 15537348]
KB	IC₅₀	0.3 nM Compound: 1b	Concentration required for inhibition of 50% human fibroblast KB cell line proliferation after 72 hr of incubation Concentration required for inhibition of 50% human fibroblast KB cell line proliferation after 72 hr of incubation	[PMID: 15537348]
KB	IC₅₀	0.002 μM Compound: docetaxel	Cytotoxicity against human KB cells Cytotoxicity against human KB cells	[PMID: 15921419]
KB	IC₅₀	0.2 nM Compound: Docetaxel	Cytotoxicity against human KB cells Cytotoxicity against human KB cells	[PMID: 16989521]
KB	IC₅₀	0.0001 μM Compound: docetaxel, 1b	Cytotoxicity against human KB cells after 72 hrs Cytotoxicity against human KB cells after 72 hrs	[PMID: 17064914]
KB	IC₅₀	0.1 nM Compound: docetaxel, 1b	Cytotoxicity against human KB cells after 72 hrs Cytotoxicity against human KB cells after 72 hrs	[PMID: 17064914]
KB	IC₅₀	11.6 μg/mL Compound: docetaxel	Cytotoxicity against human KB cells by MTT assay Cytotoxicity against human KB cells by MTT assay	[PMID: 17624790]
KB	IC₅₀	1.14 nM Compound: Taxotere	Cytotoxicity against human KB cells by SRB method Cytotoxicity against human KB cells by SRB method	[PMID: 18181575]
KB	IC₅₀	1.14 x 10^-3 μM Compound: Taxotere	Cytotoxicity against human KB cells by SRB method Cytotoxicity against human KB cells by SRB method	[PMID: 18181575]
KB	IC₅₀	2.35 μM Compound: docetaxel	Cytotoxicity against human KB cells Cytotoxicity against human KB cells	[PMID: 18701281]
KB	IC₅₀	0.0002 μM Compound: taxotere	Cytotoxicity against human KB cells after 72 hrs by neutral red staining Cytotoxicity against human KB cells after 72 hrs by neutral red staining	[PMID: 19053513]
KB	IC₅₀	0.2 nM Compound: taxotere	Cytotoxicity against human KB cells after 72 hrs by neutral red staining Cytotoxicity against human KB cells after 72 hrs by neutral red staining	[PMID: 19053513]
KB	IC₅₀	0.15 nM Compound: taxotere	Cytotoxicity against human KB cells Cytotoxicity against human KB cells	[PMID: 19572612]
KB	IC₅₀	0.2 nM Compound: docetaxel	Cytotoxicity against human KB cells after 72 hrs by MTS assay Cytotoxicity against human KB cells after 72 hrs by MTS assay	[PMID: 19655762]
KB	IC₅₀	0.4 nM Compound: Taxotere	Cytotoxicity against human KB cells assessed as growth inhibition after 72 hrs by MTS assay Cytotoxicity against human KB cells assessed as growth inhibition after 72 hrs by MTS assay	[PMID: 20053482]
KB	IC₅₀	0.15 μM Compound: Taxotere	Cytotoxicity against human KB cells Cytotoxicity against human KB cells	[PMID: 20481544]
KB	IC₅₀	0.29 μM Compound: Taxotere	Cytotoxicity against human KB cells after 72 hrs Cytotoxicity against human KB cells after 72 hrs	[PMID: 20849074]
KB	IC₅₀	0.17 nM Compound: Taxotere	Cytotoxicity against human KB cells after 72 hrs by MTS assay Cytotoxicity against human KB cells after 72 hrs by MTS assay	[PMID: 21142180]
KB	IC₅₀	0.15 nM Compound: Taxotere	Cytotoxicity against human KB cells after 72 hrs by neutral red based colorimetry assay Cytotoxicity against human KB cells after 72 hrs by neutral red based colorimetry assay	[PMID: 21443172]
KB	IC₅₀	15 nM Compound: Taxotere	Cytotoxicity against human KB cells Cytotoxicity against human KB cells	[PMID: 22050318]
KB	IC₅₀	0.17 nM Compound: taxotere	Cytotoxicity against human KB cells incubated for 72 hrs by MTS assay Cytotoxicity against human KB cells incubated for 72 hrs by MTS assay	[PMID: 23072299]
KB	IC₅₀	0.00025 μM Compound: Taxotere	Cytotoxicity against human KB cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay Cytotoxicity against human KB cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	[PMID: 23387796]
KB	IC₅₀	0.25 nM Compound: Taxotere	Cytotoxicity against human KB cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay Cytotoxicity against human KB cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	[PMID: 23387796]
KB	IC₅₀	0.0002 μM Compound: Taxotere	Cytotoxicity activity against human KB cells Cytotoxicity activity against human KB cells	[PMID: 25478997]
KB	IC₅₀	0.2 nM Compound: Taxotere	Cytotoxicity activity against human KB cells Cytotoxicity activity against human KB cells	[PMID: 25478997]
KB 3-1	CC₅₀	0.25 nM Compound: Docetaxel	Cytotoxicity against human KB-3-1 cells after 72 hrs by MTS assay Cytotoxicity against human KB-3-1 cells after 72 hrs by MTS assay	[PMID: 18485536]
LLC-PK1	GI₅₀	0.17 nM Compound: Doc, Taxotere	Growth inhibition of pig LLC-PK1 cells by Alamar Blue assay Growth inhibition of pig LLC-PK1 cells by Alamar Blue assay	[PMID: 23956835]
LLC-PK1	GI₅₀	106.6 nM Compound: Doc, Taxotere	Growth inhibition of pig LLC-PK1 cells expressing MDR1 by Alamar Blue assay Growth inhibition of pig LLC-PK1 cells expressing MDR1 by Alamar Blue assay	[PMID: 23956835]
LoVo	IC₅₀	1.97 nM Compound: Taxotere	Cytotoxicity against human LoVo cells by SRB method Cytotoxicity against human LoVo cells by SRB method	[PMID: 18181575]
LoVo	IC₅₀	1.97 x 10^-3 μM Compound: Taxotere	Cytotoxicity against human LoVo cells by SRB method Cytotoxicity against human LoVo cells by SRB method	[PMID: 18181575]
MCF7	IC₅₀	1 nM Compound: Docetaxel	Inhibitory activity against the growth of MCF-7 (human breast carcinoma) cell line after 72 hours of drug exposure Inhibitory activity against the growth of MCF-7 (human breast carcinoma) cell line after 72 hours of drug exposure	[PMID: 10617084]
MCF7	IC₅₀	235 nM Compound: Docetaxel	Inhibitory activity against the growth of MCF-7R ( multi drug resistant human breast carcinoma) cell line after 72 hours of drug exposure Inhibitory activity against the growth of MCF-7R ( multi drug resistant human breast carcinoma) cell line after 72 hours of drug exposure	[PMID: 10617084]
MCF7	IC₅₀	0.0079 μM Compound: 1b (Docetaxel)	Inhibitory activity against MCF-7 breast cancer cell line Inhibitory activity against MCF-7 breast cancer cell line	[PMID: 12031338]
MCF7	IC₅₀	4.2 μM Compound: 1b (Docetaxel)	Inhibitory activity against Adriamycin-resistant MCF-7 breast cancer cell line Inhibitory activity against Adriamycin-resistant MCF-7 breast cancer cell line	[PMID: 12031338]
MCF7	IC₅₀	1 nM Compound: Docetaxel	In vitro cytotoxicity of compound against human MCF-7 (breast) cancer cell line after 72 hr of drug exposure In vitro cytotoxicity of compound against human MCF-7 (breast) cancer cell line after 72 hr of drug exposure	[PMID: 12477344]
MCF7	IC₅₀	1 nM Compound: 1b Docetaxel	Compound was tested for its cytotoxicity by inhibiting the growth of MCF-7 cell line after 72 h Compound was tested for its cytotoxicity by inhibiting the growth of MCF-7 cell line after 72 h	[PMID: 15225730]
MCF7	IC₅₀	1 μM Compound: 2	inhibitory concentration against the growth of breast cancer MCF-7 cell line after 72 hr of exposure inhibitory concentration against the growth of breast cancer MCF-7 cell line after 72 hr of exposure	[PMID: 15501062]
MCF7	IC₅₀	0.001 μM Compound: 1b	Concentration required for inhibition of 50% human breast MCF 7 cell line proliferation after 72 hr of incubation Concentration required for inhibition of 50% human breast MCF 7 cell line proliferation after 72 hr of incubation	[PMID: 15537348]
MCF7	IC₅₀	0.02 μM Compound: docetaxel	Cytotoxicity against doxorubicin-sensitive human MCF7 cells Cytotoxicity against doxorubicin-sensitive human MCF7 cells	[PMID: 15921419]
MCF7	IC₅₀	3.3 μg/mL Compound: docetaxel	Cytotoxicity against human MCF7 cells by MTT assay Cytotoxicity against human MCF7 cells by MTT assay	[PMID: 17624790]
MCF7	IC₅₀	4 μM Compound: docetaxel	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 18226907]
MCF7	IC₅₀	1 nM Compound: docetaxel	Cytotoxicity against Pgp deficient human MCF7 cells after 72 hrs by sulforhodamine B test Cytotoxicity against Pgp deficient human MCF7 cells after 72 hrs by sulforhodamine B test	[PMID: 18465846]
MCF7	IC₅₀	3.29 μM Compound: docetaxel	Cytotoxicity against human MCF7 cells Cytotoxicity against human MCF7 cells	[PMID: 18701281]
MCF7	IC₅₀	1 nM Compound: docetaxel	Cytotoxicity against P-glycoprotein deficient wild type human MCF7 cells after 72 hrs Cytotoxicity against P-glycoprotein deficient wild type human MCF7 cells after 72 hrs	[PMID: 19239240]
MCF7	IC₅₀	215 nM Compound: docetaxel	Cytotoxicity against human MCF7 cells expressing P-glycoprotein after 72 hrs Cytotoxicity against human MCF7 cells expressing P-glycoprotein after 72 hrs	[PMID: 19239240]
MCF7	IC₅₀	0.7 nM Compound: taxotere	Cytotoxicity against human MCF7 cells Cytotoxicity against human MCF7 cells	[PMID: 19572612]
MCF7	IC₅₀	11.9 μM Compound: docetaxel	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 22560315]
MCF7	IC₅₀	180 nM Compound: Docetaxel	Antiproliferative against multidrug-resistant human MCF7 cells after 72 hrs by MTT assay Antiproliferative against multidrug-resistant human MCF7 cells after 72 hrs by MTT assay	[PMID: 24835987]
MCF7	IC₅₀	38.53 nM Compound: Docetaxel	Antiproliferative against human MCF7 cells after 72 hrs by MTT assay Antiproliferative against human MCF7 cells after 72 hrs by MTT assay	[PMID: 24835987]
MCF7	IC₅₀	59.3 nM Compound: Docetaxel	Cytotoxicity against human ER-positive MCF7 cells Cytotoxicity against human ER-positive MCF7 cells	[PMID: 24890652]
MCF7	IC₅₀	>1000 nM Compound: Docetaxel	Cytotoxicity against human taxoid-resistant MCF7 cells Cytotoxicity against human taxoid-resistant MCF7 cells	[PMID: 24890652]
MCF7	IC₅₀	1 nM Compound: Docetaxel	Cytotoxicity against human MCF7 cells by MTT assay Cytotoxicity against human MCF7 cells by MTT assay	[PMID: 25047938]
MCF7	IC₅₀	139.8 μM Compound: Docetaxel	Cytotoxicity against human MCF7 cells over-expressing CYP1B1 after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells over-expressing CYP1B1 after 48 hrs by MTT assay	[PMID: 25799264]
MCF7	IC₅₀	27.6 μM Compound: Docetaxel	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 25799264]
MCF7	IC₅₀	0.005 μM Compound: DOC	Cytotoxicity against human MCF7 cells assessed as growth inhibition after 96 hrs by SRB assay Cytotoxicity against human MCF7 cells assessed as growth inhibition after 96 hrs by SRB assay	[PMID: 25817774]
MCF7	IC₅₀	1 nM Compound: docetaxel	Concentration required to inhibit growth of human tumor MCF-7 (breast) cell line. Concentration required to inhibit growth of human tumor MCF-7 (breast) cell line.	[PMID: 8831755]
MCF7	IC₅₀	235 nM Compound: docetaxel	Concentration required to inhibit growth of human tumor MFC7-R (breast) cell line. Concentration required to inhibit growth of human tumor MFC7-R (breast) cell line.	[PMID: 8831755]
MCF7	IC₅₀	1 nM Compound: Docetaxel	Growth inhibition of human mammary carcinoma (MCF-7) cell line Growth inhibition of human mammary carcinoma (MCF-7) cell line	[PMID: 9022793]
MCF7	IC₅₀	1 nM Compound: Docetaxel	Inhibition of the growth against human mammary carcinoma (MCF-7) cell line after 72 hr exposure Inhibition of the growth against human mammary carcinoma (MCF-7) cell line after 72 hr exposure	[PMID: 9022794]
MCF7	IC₅₀	1 nM Compound: Docetaxel	Cytotoxicity against human breast MCF-7 cancer cell lines Cytotoxicity against human breast MCF-7 cancer cell lines	10.1016/S0960-894X(01)80298-5
MCF7	IC₅₀	235 nM Compound: Docetaxel	Cytotoxicity against adriamycin resistant human breast MCF-7 cancer cell lines Cytotoxicity against adriamycin resistant human breast MCF-7 cancer cell lines	10.1016/S0960-894X(01)80298-5
MCF7	IC₅₀	1 nM Compound: Docetaxel	Cytotoxicity was evaluated in vitro against MCF-7 (mammary carcinoma) human tumor cell lines Cytotoxicity was evaluated in vitro against MCF-7 (mammary carcinoma) human tumor cell lines	10.1016/S0960-894X(01)80568-0
MCF7	IC₅₀	1 nM Compound: Docetaxal	Cytotoxicity was evaluated against MCF-7 mammary carcinoma human breast cancer cell line Cytotoxicity was evaluated against MCF-7 mammary carcinoma human breast cancer cell line	10.1016/S0960-894X(96)00595-1
MCF7R	IC₅₀	723 nM Compound: Docetaxel	Cytotoxicity against human mammary tumor cell line MCF7-R Cytotoxicity against human mammary tumor cell line MCF7-R	[PMID: 16298526]
MCF7R	IC₅₀	235 nM Compound: Docetaxel	Cytotoxicity against human MCF7/R cells by MTT assay Cytotoxicity against human MCF7/R cells by MTT assay	[PMID: 25047938]
MCF7R	IC₅₀	235 nM Compound: Docetaxel	Growth inhibition of human mammary carcinoma 180 fold resistant to doxorubicin (MCF-7-R) cell line Growth inhibition of human mammary carcinoma 180 fold resistant to doxorubicin (MCF-7-R) cell line	[PMID: 9022793]
MCF7R	IC₅₀	235 nM Compound: Docetaxel	Inhibition of the growth against human mammary carcinoma 180 fold resistant to doxorubicin (MCF-7-R) cell line after 72 hr exposure Inhibition of the growth against human mammary carcinoma 180 fold resistant to doxorubicin (MCF-7-R) cell line after 72 hr exposure	[PMID: 9022794]
MCF7R	IC₅₀	235 nM Compound: Docetaxal	Cytotoxicity was evaluated against MCF7-R (mammary carcinoma 180-fold resistant to doxorubicin, expressing MDR phenotype) human breast cancer cell line Cytotoxicity was evaluated against MCF7-R (mammary carcinoma 180-fold resistant to doxorubicin, expressing MDR phenotype) human breast cancer cell line	10.1016/S0960-894X(96)00595-1
MCF7S	IC₅₀	1 nM Compound: Docetaxel	Cytotoxicity against human mammary tumor cell line MCF7-S Cytotoxicity against human mammary tumor cell line MCF7-S	[PMID: 16298526]
MDA-MB-231	IC₅₀	0.018 nM Compound: Taxotere	Cytotoxicity against human MDA231 cells after 72 hrs by MTS assay Cytotoxicity against human MDA231 cells after 72 hrs by MTS assay	[PMID: 21142180]
MDA-MB-231	IC₅₀	1 nM Compound: DTX	Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 24564494]
MDA-MB-231	IC₅₀	16 nM Compound: Docetaxel	Cytotoxicity against human triple negative MDA-MB-231 cells Cytotoxicity against human triple negative MDA-MB-231 cells	[PMID: 24890652]
MDA-MB-435	IC₅₀	0.25 nM Compound: Taxotere	Cytotoxicity against human MDA435 cells after 72 hrs by MTS assay Cytotoxicity against human MDA435 cells after 72 hrs by MTS assay	[PMID: 21142180]
MDA-MB-435	IC₅₀	2.7 nM Compound: Docetaxel	Cytotoxicity against human MDA-MB-435 cells Cytotoxicity against human MDA-MB-435 cells	[PMID: 24890652]
MDA-MB-468	IC₅₀	69.1 nM Compound: Docetaxel	Cytotoxicity against human triple negative MDA-MB-468 cells Cytotoxicity against human triple negative MDA-MB-468 cells	[PMID: 24890652]
MHCC97H	IC₅₀	22.4 nM Compound: Docetaxel	Antiproliferative activity against human MHCC97H after 72 hrs by CellTiter Glo assay Antiproliferative activity against human MHCC97H after 72 hrs by CellTiter Glo assay	[PMID: 22320354]
MRC5	IC₅₀	0.0005 μM Compound: Taxotere	Cytotoxicity activity against human MRC5 cells Cytotoxicity activity against human MRC5 cells	[PMID: 25478997]
MRC5	IC₅₀	0.5 nM Compound: Taxotere	Cytotoxicity activity against human MRC5 cells Cytotoxicity activity against human MRC5 cells	[PMID: 25478997]
MX1	IC₅₀	0.14 nM Compound: docetoxel	Displacement of [125I]JV1-42 from GHRH receptor expressed in human MX1 cells Displacement of [125I]JV1-42 from GHRH receptor expressed in human MX1 cells	[PMID: 17261802]
NCI/ADR-RES	IC₅₀	235 nM Compound: Docetaxel	In vitro cytotoxicity of compound against human MCF-7-MDR (breast) cancer cell line after 72 hr of drug exposure In vitro cytotoxicity of compound against human MCF-7-MDR (breast) cancer cell line after 72 hr of drug exposure	[PMID: 12477344]
NCI/ADR-RES	GI₅₀	196 nM Compound: Doc, Taxotere	Growth inhibition of P-gp expressing human NCI-ADR-RES cells by Alamar Blue assay Growth inhibition of P-gp expressing human NCI-ADR-RES cells by Alamar Blue assay	[PMID: 23956835]
NCI/ADR-RES	IC₅₀	5.18 μM Compound: DOC	Cytotoxicity against human MCF7/ADR cells assessed as growth inhibition after 96 hrs by SRB assay Cytotoxicity against human MCF7/ADR cells assessed as growth inhibition after 96 hrs by SRB assay	[PMID: 25817774]
NCI-H460	IC₅₀	0.0097 μM Compound: docetaxel	Cytotoxicity against human NCI-H460 cells after 72 hrs by SRB assay Cytotoxicity against human NCI-H460 cells after 72 hrs by SRB assay	[PMID: 19028425]
OVCAR-3	IC₅₀	1.2 nM Compound: 2 (docetaxel)	Inhibitory concentration required against OVCAR-3 human ovarian cancer cell line was determined Inhibitory concentration required against OVCAR-3 human ovarian cancer cell line was determined	[PMID: 10397492]
OVCAR-8	GI₅₀	0.5 nM Compound: Doc, Taxotere	Growth inhibition of human OVCAR8 cells by Alamar Blue assay Growth inhibition of human OVCAR8 cells by Alamar Blue assay	[PMID: 23956835]
P388	GI₅₀	0.78 ng/mL Compound: Docetaxel	Cytotoxic activity against mouse leukemia P388 cell line Cytotoxic activity against mouse leukemia P388 cell line	[PMID: 12482420]
P388	IC₅₀	0.13 μg/mL Compound: 13a	The concentration required to 50% inhibition of the P388 leukemic cell proliferation The concentration required to 50% inhibition of the P388 leukemic cell proliferation	[PMID: 1672159]
P388	IC₅₀	2 nM Compound: docetaxel	Cytotoxicity against mouse P388 cells Cytotoxicity against mouse P388 cells	[PMID: 18651728]
P388	IC₅₀	277 nM Compound: docetaxel	Cytotoxicity against adriamycin-resistant mouse P388 cells expressing p-glycoprotein Cytotoxicity against adriamycin-resistant mouse P388 cells expressing p-glycoprotein	[PMID: 18651728]
P388	IC₅₀	0.008 μg/mL Compound: docetaxel	In vitro cytotoxicity against murine P388 leukemia cell line In vitro cytotoxicity against murine P388 leukemia cell line	[PMID: 7914541]
P388	IC₅₀	1.5 μg/mL Compound: docetaxel	In vitro cytotoxicity against murine P388 doxorubicin resistant leukemia cell line In vitro cytotoxicity against murine P388 doxorubicin resistant leukemia cell line	[PMID: 7914541]
P388	GI₅₀	6.74 ng/mL Compound: 2 (Docetaxel)	Concentration required to inhibit the growth of mouse leukemia (P388) cell lines by 50% on 72 h continuous exposure Concentration required to inhibit the growth of mouse leukemia (P388) cell lines by 50% on 72 h continuous exposure	[PMID: 9871592]
P388	IC₅₀	0.04 μg/mL Compound: 2 (docetaxel)	In vitro cytotoxicity against murine P388 lymphocytic leukemia cells In vitro cytotoxicity against murine P388 lymphocytic leukemia cells	10.1016/0960-894X(95)00118-D
P388	IC₅₀	1.86 μM Compound: Docetaxel	In vitro cytotoxicity against doxorubicin resistant P388 cell lines In vitro cytotoxicity against doxorubicin resistant P388 cell lines	10.1016/S0960-894X(01)80298-5
P388	IC₅₀	9.9 nM Compound: Docetaxel	In vitro cytotoxicity against murine P388 cell lines In vitro cytotoxicity against murine P388 cell lines	10.1016/S0960-894X(01)80298-5
P388	GI₅₀	1.62 ng/mL Compound: 2	Compound was tested for growth inhibitory activity after 72 hr of continuous exposure against mouse leukemia P388 Compound was tested for growth inhibitory activity after 72 hr of continuous exposure against mouse leukemia P388	10.1016/S0960-894X(97)10128-7
PC-12	GI₅₀	11.7 ng/mL Compound: 2	Cytotoxic activity against PC-12 human non-small cell lung cancer cell line Cytotoxic activity against PC-12 human non-small cell lung cancer cell line	[PMID: 11212122]
PC-12	GI₅₀	11.7 ng/mL Compound: 2 (Docetaxel)	Growth inhibition of 50% of human non-small cell lung cancer (PC-12) cell line in MTT assay; 11.7-72.7 Growth inhibition of 50% of human non-small cell lung cancer (PC-12) cell line in MTT assay; 11.7-72.7	[PMID: 11909723]
PC-12	GI₅₀	42.2 ng/mL Compound: 2 (Docetaxel)	Concentration required to obtain half of the maximal inhibition for cell growth in human non-small cell lung cancer cell line(PC-12) was determined by using MTT assay when the cells were exposed to compound for 72 hr Concentration required to obtain half of the maximal inhibition for cell growth in human non-small cell lung cancer cell line(PC-12) was determined by using MTT assay when the cells were exposed to compound for 72 hr	[PMID: 12270153]
PC-12	GI₅₀	14.9 ng/mL Compound: Docetaxel	Cytotoxic activity against human lung cancer PC-12 cell line Cytotoxic activity against human lung cancer PC-12 cell line	[PMID: 12482420]
PC-12	GI₅₀	53.4 ng/mL Compound: 2 (Docetaxel)	Concentration required to inhibit the growth of human lung cancer (PC-12)cell lines by 50% on 72 hr continuous exposure Concentration required to inhibit the growth of human lung cancer (PC-12)cell lines by 50% on 72 hr continuous exposure	[PMID: 9871592]
PC-12	GI₅₀	19.1 ng/mL Compound: 2	Compound was tested for growth inhibitory activity after 72 hr of continuous exposure against human lung cancer cell line PC-12 Compound was tested for growth inhibitory activity after 72 hr of continuous exposure against human lung cancer cell line PC-12	10.1016/S0960-894X(97)10128-7
PC-3	IC₅₀	54.8 μM Compound: docetaxel	Cytotoxicity against human PC3 cells after 48 hrs by MTT assay Cytotoxicity against human PC3 cells after 48 hrs by MTT assay	[PMID: 18226907]
PC-3	IC₅₀	2.77 μM Compound: docetaxel	Cytotoxicity against human PC3 cells Cytotoxicity against human PC3 cells	[PMID: 18701281]
PC-3	IC₅₀	1.4 nM Compound: Taxotere	Cytotoxicity against human PC3 cells after 72 hrs by MTS assay Cytotoxicity against human PC3 cells after 72 hrs by MTS assay	[PMID: 21142180]
PC-3	GI₅₀	2.5 nM Compound: Doc, Taxotere	Growth inhibition of human PC3 cells after 72 hrs by Alamar Blue assay Growth inhibition of human PC3 cells after 72 hrs by Alamar Blue assay	[PMID: 23956835]
PC-3	GI₅₀	54 nM Compound: Doc, Taxotere	Growth inhibition of P-gp expressing docetaxel-resistant human PC3 cells after 72 hrs by Alamar Blue assay Growth inhibition of P-gp expressing docetaxel-resistant human PC3 cells after 72 hrs by Alamar Blue assay	[PMID: 23956835]
PC-6	GI₅₀	0.408 ng/mL Compound: 2	Cytotoxic activity against PC-6 human small cell lung cancer Cytotoxic activity against PC-6 human small cell lung cancer	[PMID: 11212122]
PC-6	GI₅₀	39.6 ng/mL Compound: 2	Cytotoxic activity against PC-6/VCR29-9 vincristine resistant cell line expressing P-gp Cytotoxic activity against PC-6/VCR29-9 vincristine resistant cell line expressing P-gp	[PMID: 11212122]
PC-6	GI₅₀	0.408 ng/mL Compound: 2 (Docetaxel)	Growth inhibition of 50% of human small cell lung cancer (PC-6) cell line in MTT assay; 0.408-2.55 Growth inhibition of 50% of human small cell lung cancer (PC-6) cell line in MTT assay; 0.408-2.55	[PMID: 11909723]
PC-6	GI₅₀	39.6 ng/mL Compound: 2 (Docetaxel)	Growth inhibition of 50% of vincristine-resistant cell line expressing P-glycoprotein (PC-6/VCR) in MTT assay; 39.6-230 Growth inhibition of 50% of vincristine-resistant cell line expressing P-glycoprotein (PC-6/VCR) in MTT assay; 39.6-230	[PMID: 11909723]
PC-6	GI₅₀	1.48 ng/mL Compound: 2 (Docetaxel)	Concentration required to obtain half of the maximal inhibition for cell growth in human small cell lung cancer(PC-6) was determined by using MTT assay when the cells were exposed to compound for 72 hr Concentration required to obtain half of the maximal inhibition for cell growth in human small cell lung cancer(PC-6) was determined by using MTT assay when the cells were exposed to compound for 72 hr	[PMID: 12270153]
PC-6	GI₅₀	135 ng/mL Compound: 2 (Docetaxel)	Concentration required to obtain half of the maximal inhibition for cell growth in vincristine-resistant cell line expressing P-glycoprotein (PC-6/VCR29-9) was determined by using MTT assay when the cells were exposed to compound for 72 hr Concentration required to obtain half of the maximal inhibition for cell growth in vincristine-resistant cell line expressing P-glycoprotein (PC-6/VCR29-9) was determined by using MTT assay when the cells were exposed to compound for 72 hr	[PMID: 12270153]
PC-6	GI₅₀	0.41 ng/mL Compound: Docetaxel	Cytotoxic activity against human lung cancer PC-6 cell line Cytotoxic activity against human lung cancer PC-6 cell line	[PMID: 12482420]
PC-6	GI₅₀	1.13 ng/mL Compound: 2 (Docetaxel)	Concentration required to inhibit the growth of human lung cancer (PC-6)cell lines by 50% on 72 hr continuous exposure Concentration required to inhibit the growth of human lung cancer (PC-6)cell lines by 50% on 72 hr continuous exposure	[PMID: 9871592]
PC-6	GI₅₀	1.16 ng/mL Compound: 2	Compound was tested for growth inhibitory activity after 72 hr of continuous exposure against human lung cancer cell line PC-6 Compound was tested for growth inhibitory activity after 72 hr of continuous exposure against human lung cancer cell line PC-6	10.1016/S0960-894X(97)10128-7
PC-6	GI₅₀	173 ng/mL Compound: 2	Compound was tested for growth inhibitory activity after 72 hr of continuous exposure against vincristine resistant cancer cell line PC-6/VCR Compound was tested for growth inhibitory activity after 72 hr of continuous exposure against vincristine resistant cancer cell line PC-6/VCR	10.1016/S0960-894X(97)10128-7
PLC-PRF-5	IC₅₀	12 nM Compound: Docetaxel	Antiproliferative activity against human PLC/PRF/5 cells Antiproliferative activity against human PLC/PRF/5 cells	[PMID: 22320354]
PLC-PRF-5	IC₅₀	16.7 nM Compound: Docetaxel	Antiproliferative activity against human PLC/PRF/5 after 72 hrs by CellTiter Glo assay Antiproliferative activity against human PLC/PRF/5 after 72 hrs by CellTiter Glo assay	[PMID: 22320354]
SGC-7901	IC₅₀	0.0084 μM Compound: docetaxel	Cytotoxicity against human SGC7901 cells after 72 hrs by SRB assay Cytotoxicity against human SGC7901 cells after 72 hrs by SRB assay	[PMID: 19028425]
SK-BR-3	IC₅₀	4.7 nM Compound: 2 (docetaxel)	Inhibitory concentration required against SK-BR-3 human breast cancer cell line was determined Inhibitory concentration required against SK-BR-3 human breast cancer cell line was determined	[PMID: 10397492]
SK-LU-1	IC₅₀	1.8 nM Compound: 2 (docetaxel)	Inhibitory concentration required against SK-LU-1 human lung cancer cell line was determined Inhibitory concentration required against SK-LU-1 human lung cancer cell line was determined	[PMID: 10397492]
SK-OV-3	IC₅₀	3.4 nM Compound: Docetaxel	Cytotoxicity against human SKOV3 cells after 72 hrs by SRB assay Cytotoxicity against human SKOV3 cells after 72 hrs by SRB assay	[PMID: 18524425]
SK-OV-3	IC₅₀	3.4 x 10^-3 μM Compound: Docetaxel	Cytotoxicity against human SKOV3 cells after 72 hrs by SRB assay Cytotoxicity against human SKOV3 cells after 72 hrs by SRB assay	[PMID: 18524425]
SK-OV-3	IC₅₀	2.35 μM Compound: docetaxel	Cytotoxicity against human SKOV3 cells Cytotoxicity against human SKOV3 cells	[PMID: 18701281]
SK-OV-3	IC₅₀	0.51 nM Compound: Taxotere	Cytotoxicity against human SKOV3 cells after 72 hrs by MTS assay Cytotoxicity against human SKOV3 cells after 72 hrs by MTS assay	[PMID: 21142180]
SK-OV-3	IC₅₀	5 nM Compound: 2, DTX, Taxotere	Cytotoxicity against human SKOV3 cells after 48 hrs by MTT assay Cytotoxicity against human SKOV3 cells after 48 hrs by MTT assay	[PMID: 24269481]
SMMC-7721	IC₅₀	2.73 μM Compound: docetaxel	Cytotoxicity against human SMMC7721 cells Cytotoxicity against human SMMC7721 cells	[PMID: 18701281]
SMMC-7721	IC₅₀	2 nM Compound: Docetaxel	Antiproliferative activity against human SMMC7721 after 72 hrs by CellTiter Glo assay Antiproliferative activity against human SMMC7721 after 72 hrs by CellTiter Glo assay	[PMID: 22320354]
SNU-182	IC₅₀	39.2 nM Compound: Docetaxel	Antiproliferative activity against human SNU182 after 72 hrs by CellTiter Glo assay Antiproliferative activity against human SNU182 after 72 hrs by CellTiter Glo assay	[PMID: 22320354]
SNU-387	IC₅₀	4.3 nM Compound: Docetaxel	Antiproliferative activity against human SNU387 after 72 hrs by CellTiter Glo assay Antiproliferative activity against human SNU387 after 72 hrs by CellTiter Glo assay	[PMID: 22320354]
SNU-398	IC₅₀	16.6 nM Compound: Docetaxel	Antiproliferative activity against human SNU398 cells Antiproliferative activity against human SNU398 cells	[PMID: 22320354]
SNU-398	IC₅₀	17.6 nM Compound: Docetaxel	Antiproliferative activity against human SNU398 after 72 hrs by CellTiter Glo assay Antiproliferative activity against human SNU398 after 72 hrs by CellTiter Glo assay	[PMID: 22320354]
SNU-423	IC₅₀	10.8 nM Compound: Docetaxel	Antiproliferative activity against human SNU423 after 72 hrs by CellTiter Glo assay Antiproliferative activity against human SNU423 after 72 hrs by CellTiter Glo assay	[PMID: 22320354]
SNU-449	IC₅₀	>100 nM Compound: Docetaxel	Antiproliferative activity against human SNU449 after 72 hrs by CellTiter Glo assay Antiproliferative activity against human SNU449 after 72 hrs by CellTiter Glo assay	[PMID: 22320354]
SNU-475	IC₅₀	20.5 nM Compound: Docetaxel	Antiproliferative activity against human SNU475 after 72 hrs by CellTiter Glo assay Antiproliferative activity against human SNU475 after 72 hrs by CellTiter Glo assay	[PMID: 22320354]
U-87MG ATCC	IC₅₀	20.72 μg/mL Compound: Docetaxel	Cytotoxicity against human U87 cells after 72 hrs by MTT assay Cytotoxicity against human U87 cells after 72 hrs by MTT assay	10.1007/s00044-013-0582-8
WI-38	IC₅₀	>10 μM Compound: docetaxel	Cytotoxicity against human WI38 cells after 72 hrs by SRB assay Cytotoxicity against human WI38 cells after 72 hrs by SRB assay	[PMID: 19028425]
WiDr	IC₅₀	0.43 nM Compound: 2 (docetaxel)	Inhibitory concentration required against WiDr human colon cancer cell line was determined Inhibitory concentration required against WiDr human colon cancer cell line was determined	[PMID: 10397492]

In Vitro

Docetaxel (0-1000 nM; 24-96 h) Trihydrate inhibits the growth of MCF7 and MDA-MB-231 cells, exhibiting biphasic sensitivity characteristics, with an IC₇₅ of approximately 2 nM in MDA-MB-231 and approximately 4 nM in MCF7^[5].
Docetaxel (2-100 nM; 8-48 h) Trihydrate induces subG1 hypodiploidy, whereas 100 nM induces G2/M mitotic arrest^[5].
Docetaxel (2 nM; 24 h) Trihydrate induces subdiploidy in MDA-MB-231, a process that requires passage through mitosis and is attenuated by MG132 (HY-13259), whereas 100 nM causes mitotic arrest^[5].
Docetaxel (4-100 nM; 24 h) Trihydrate induces abnormal mitosis with small mononuclei in MCF7 cells at 4 nM, whereas 100 nM induces multinucleated cells^[5].
Docetaxel (4-100 nM; 24 h) Trihydrate induces apoptosis in detached MCF7 cells primarily after mitotic arrest at 100 nM, whereas 4 nM leads to non-apoptotic/necrotic death^[5].
Docetaxel Trihydrate upregulates TNFRSF6/FAS in MCF7 and MDA-MB-231 cells in a concentration-independent manner; at 100 nM, it increases phosphorylation of p53, Bax, and Bcl-2, whereas 4 nM produces higher p21 in MCF7; the DNA damage marker phosphorylated H2AX is notably induced in MDA-MB-231^[5].
Docetaxel (2-100 nM) Trihydrate produces dose- and cell line-dependent transcriptional profiles in MCF7 and MDA-MB-231, involving p53 targets at 4 nM and mitosis/checkpoint genes at 100 nM^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.

In Vivo

Docetaxel (DTX) (oral granule formulation; 25‑50 mg/kg; repeated once-daily administration) exhibits sex-dependent maximum tolerated dose and differential tissue distribution characteristics in FVB mice; high doses can cause kidney injury^[1].
Docetaxel (15-150 mg/kg; single bolus) Trihydrate in Sprague-Dawley rats, intraperitoneal administration compared with intravenous administration significantly increases peritoneal fluid drug exposure, reduces systemic plasma exposure, and alters drug accumulation levels in multiple peritoneal organs^[3].
Docetaxel (DTX) (10 mg/kg; single intraperitoneal injection; 4 days) Trihydrate decreases SOD activity and increases CAT activity in rat liver tissue^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS No. 148408-66-6
Appearance Solid
Masse moléculaire 861.93
Formule C₄₃H₅₉NO₁₇
Color White to off-white
SMILES

O=C(OC(C)(C)C)N[C@H]([C@H](C(O[C@@H]1C(C)=C([C@@H](O)C([C@@]2(C)[C@]([C@@](CO3)(OC(C)=O)[C@@]3([H])C[C@@H]2O)([H])[C@@H]4OC(C5=CC=CC=C5)=O)=O)C(C)(C)[C@@]4(O)C1)=O)O)C6=CC=CC=C6.O.O.O
Synonyms

RP-56976 Trihydrate
Livraison

Room temperature in continental US; may vary elsewhere.

Stockage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (183)

All Apoptosis AnalysisWBCell Proliferation/Viability Assay

Sort by:

Journal Impact Factor

Signal Transduct Target Ther

Targeting oncogenic TβRI signaling inhibits androgen-independent prostate cancer growth and metastasis. [Abstract]

2026 Jun 17;11(1):238. PMID: 42303991
Signal Transduct Target Ther

Selective depletion of tumor-associated SAMHD1 enhances chemotherapeutic efficacy and antitumor immune responses. [Abstract]

2025 Dec 15;10(1):406. PMID: 41392286
Signal Transduct Target Ther

Elaiophylin triggers paraptosis and preferentially kills ovarian cancer drug-resistant cells by inducing MAPK hyperactivation. [Abstract]

2022 Sep 12;7(1):317. PMID: 36097006
J Hematol Oncol

Myeloid-like tumor hybrid cells in bone marrow promote progression of prostate cancer bone metastasis. [Abstract]

2023 May 3;16(1):46. PMID: 37138326

Docetaxel Trihydrate purchased from MedChemExpress. Usage Cited in: J Hematol Oncol. 2023 May 3;16(1):46. [Abstract]

Under docetaxel treatment (0.5 nM, 1 nM, 2.5 nM, 5 nM, 10 nM, 20 nM, 48 hours), myeloid-like tumor hybrid cells were less sensitive than the RM1 cell line.
J Clin Oncol

2026 Mar 2.
Mol Cancer

2026 May 13.
Mol Cancer

Autologous patient-derived exhausted nano T-cells exploit tumor immune evasion to engage an effective cancer therapy. [Abstract]

2024 May 9;23(1):83. PMID: 38730475
Cancer Discov

Targeting KRAS codon 13 mutations using direct combination approaches in non-small cell lung cancer. [Abstract]

2026 Jun 22. PMID: 42329102
Adv Mater

Soft Extrudable Dendritic Particles with Nanostructured Tendrils for Local Adhesion and Drug Release to Bladder Cancers. [Abstract]

2025 Jul 4:e2505231. PMID: 40611758
Eur Urol

Taxane-induced Attenuation of the CXCR2/BCL-2 Axis Sensitizes Prostate Cancer to Platinum-based Treatment. [Abstract]

2021 Jun;79(6):722-733. PMID: 33153817
Cancer Res

Targeting Sialylation Enhances the Therapeutic Efficacy of the Nectin-4-Targeted Antibody-Drug Conjugate Enfortumab Vedotin in Bladder Cancer. [Abstract]

2025 Oct 9. PMID: 41066596
Adv Funct Mater

2023 Dec 15.
ACS Nano

Metabolic Control by Heat Stress Determining Cell Fate to Ferroptosis for Effective Cancer Therapy. [Abstract]

2021 Apr 27;15(4):7179-7194. PMID: 33861924
Redox Biol

2026 Sep 2:97:104376. PMID: 42700475
Sci Transl Med

TSPAN8+ myofibroblastic cancer-associated fibroblasts promote chemoresistance in patients with breast cancer. [Abstract]

2024 Apr 3;16(741):eadj5705. PMID: 38569015

Docetaxel Trihydrate purchased from MedChemExpress. Usage Cited in: Sci Transl Med. 2024 Apr 3;16(741):eadj5705. [Abstract]

Growth inhibition by docetaxel (Doc) (0–10 μM) in TS− or TS+ CAFs isolated from patients with BC was observed. The survival rates of TSPAN8+ CAFs were enhanced compared with TSPAN8− CAFs when challenged with an equal dosage of docetaxel.
Biomark Res

circCYP24A1 promotes Docetaxel resistance in prostate Cancer by Upregulating ALDH1A3. [Abstract]

2022 Jul 13;10(1):48. PMID: 35831872
Acta Pharm Sin B

Intracellular aggregation of peptide-reprogrammed small molecule nanoassemblies enhances cancer chemotherapy and combinatorial immunotherapy. [Abstract]

2021 Apr;11(4):1069-1082. PMID: 33996418
J Clin Invest

Targeting Wnt/β-Catenin and circadian regulator restores PRC2/EZH2 controlled chromatin bivalency and suppresses cell state diversity. [Abstract]

2026 Mar 17:e200260. PMID: 41842971
J Exp Clin Cancer Res

LncRNA SNHG4 promotes prostate cancer cell survival and resistance to enzalutamide through a let-7a/RREB1 positive feedback loop and a ceRNA network. [Abstract]

2023 Aug 18;42(1):209. PMID: 37596700
Adv Sci (Weinh)

Red Blood Cells Internalize Extracellular DNA via Apoptotic Bodies with Clinical Relevance to Cancer Patients. [Abstract]

2026 Mar;13(13):e11408. PMID: 41486873
Adv Sci (Weinh)

Osteoblast-Derived ECM1 Promotes Anti-Androgen Resistance in Bone Metastatic Prostate Cancer. [Abstract]

2025 Jan;12(2):e2407662. PMID: 39563492

Docetaxel Trihydrate purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Jan;12(2):e2407662. [Abstract]

Representative images and quantitative analysis of surviving clones after treatment of C4-2B and LNCaP cells with PBS or ECM1 protein (200 ng/mL) in the presence of docetaxel (10 μM) were shown.

Docetaxel Trihydrate purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Jan;12(2):e2407662. [Abstract]

Flow cytometry analysis showed representative images and quantification of apoptosis in C4-2B and LNCaP cells in the presence of docetaxel (10 μM). Docetaxel caused PCa cell apoptosis compared to that in the vehicle group.
Cell Rep Med

Sex-biased intratumoral microbiome influences tumor molecular and immune landscape and disease outcomes. [Abstract]

2026 May 19;7(5):102757. PMID: 42013847
Cell Rep Med

A human patient-derived organoid biobank to model tumor heterogeneity and therapeutic vulnerability for oral squamous cell carcinoma. [Abstract]

2026 Feb 17;7(2):102622. PMID: 41707653
Cell Rep Med

CAN-Scan: A multi-omic phenotype-driven precision oncology platform identifies prognostic biomarkers of therapy response for colorectal cancer. [Abstract]

2025 Apr 15;6(4):102053. PMID: 40187357
Cell Rep Med

Using patient-derived organoids to predict locally advanced or metastatic lung cancer tumor response: A real-world study. [Abstract]

2023 Feb 21;4(2):100911. PMID: 36657446
Biomaterials

Sustained potentiation of bystander killing via PTEN-loss driven macropinocytosis targeted peptide-drug conjugate therapy in metastatic triple-negative breast cancer. [Abstract]

2022 Oct:289:121783. PMID: 36084486
J Transl Int Med

Anti-SIA-cIgG enhances chemotherapy effectiveness through PTPN13-regulated tumor stemness in head and neck squamous cell carcinoma. [Abstract]

2026 Mar 26;14(2):237-258. PMID: 42046805
J Control Release

Macropinocytosis-targeted peptide-docetaxel conjugate for bystander pancreatic cancer treatment. [Abstract]

2024 Dec:376:829-841. PMID: 39491626
J Control Release

Effective combination of liposome-targeted chemotherapy and PD-L1 blockade of murine colon cancer. [Abstract]

2023 Jan:353:490-506. PMID: 36460179
J Control Release

Management of lymph node metastasis via local chemotherapy can prevent distant metastasis and improve survival in mice. [Abstract]

2021 Jan 10:329:847-857. PMID: 33065097
Cell Death Dis

PMEPA1 modulates YAP1 nuclear translocation to disrupt EMT subtypes and promote metastasis in Biliary tract cancer. [Abstract]

2026 Apr 3;17(1):449. PMID: 41932868
Cell Death Dis

AKT1 phosphorylates PRMT7 to promote GLUD1 methylation and gastric cancer progression. [Abstract]

2026 Mar 24;17(1):363. PMID: 41876450
Cell Death Dis

Both direct and indirect suppression of MCL1 synergizes with BCLXL inhibition in preclinical models of gastric cancer. [Abstract]

2025 Mar 12;16(1):170. PMID: 40075071
Cell Death Dis

Single-cell transcriptome profiles the heterogeneity of tumor cells and microenvironments for different pathological endometrial cancer and identifies specific sensitive drugs. [Abstract]

2024 Aug 7;15(8):571. PMID: 39112478
Pharmacol Res

Time-dependent proteomics and drug response in expanding cancer cells. [Abstract]

2024 Jun:204:107208. PMID: 38729587
Cancer Lett

Chemoresistance-motility signature of molecular evolution to chemotherapy in non-muscle-invasive bladder cancer and its clinical implications. [Abstract]

2025 Feb 1:610:217339. PMID: 39608442
Cancer Lett

The CAIX inhibitor SLC-0111 exerts anti-cancer activity on gastric cancer cell lines and resensitizes resistant cells to 5-Fluorouracil, taxane-derived, and platinum-based drugs. [Abstract]

2023 Sep 1:571:216338. PMID: 37549770
J Immunother Cancer

ATM/NEMO signaling modulates the expression of PD-L1 following docetaxel chemotherapy in prostate cancer. [Abstract]

2021 Jul;9(7):e001758. PMID: 34301812
Phytomedicine

Artemisitene induces apoptosis of breast cancer cells by targeting FDFT1 and inhibits the growth of breast cancer patient-derived organoids. [Abstract]

2024 Dec:135:156155. PMID: 39461203
Phytomedicine

Sculponeatin A promotes the ETS1-SYVN1 interaction to induce SLC7A11/xCT-dependent ferroptosis in breast cancer. [Abstract]

2023 Aug:117:154921. PMID: 37327642
Phytomedicine

Compound K is a potential clinical anticancer agent in prostate cancer by arresting cell cycle. [Abstract]

2023 Jan:109:154584. PMID: 36610114
Phytomedicine

Traditional Chinese medicine CFF-1 exerts a potent anti-tumor immunity to hinder tumor growth and metastasis in prostate cancer through EGFR/JAK1/STAT3 pathway to inhibit PD-1/PD-L1 checkpoint signaling. [Abstract]

2022 May:99:153939. PMID: 35172257
Mater Today Bio

Mannosylated graphene oxide nanotherapeutics co-delivering docetaxel and a STING agonist reprogram myeloid cells and potentiate antitumor immunity. [Abstract]

2026 Mar 31:38:103086. PMID: 42006712
ACS Sens

Cryopreservable Through-Hole Arrays for the High-Throughput Three-Dimensional Smartphone-Based Cell Colorimetric Assay. [Abstract]

2023 Feb 24;8(2):543-554. PMID: 36705290
Genome Med

Genomic and transcriptomic analysis of breast cancer identifies novel signatures associated with response to neoadjuvant chemotherapy. [Abstract]

2024 Jan 12;16(1):11. PMID: 38217005
Cell Death Discov

2026 Jul 8. PMID: 42420245
J Transl Med

2026 Jul 11. PMID: 42436511
J Colloid Interface Sci

Smart dual responsive nanocarriers with reactive oxygen species amplification assisted synergistic chemotherapy against prostate cancer. [Abstract]

2022 May 2;622:789-803. PMID: 35544966
Proc Natl Acad Sci U S A

Computational drug discovery for castration-resistant prostate cancers through in vitro drug response modeling. [Abstract]

2023 Apr 25;120(17):e2218522120. PMID: 37068243
Diabetes

FGF13-sensitive alteration of Parkin safeguards mitochondrial homeostasis in endothelium of diabetic nephropathy. [Abstract]

2023 Jan 1;72(1):97-111. PMID: 36256844
Oncogene

HOMER3 drives oral squamous cell carcinoma progression through TRPV6 calcium influx and TUBB3 microtubule stabilization. [Abstract]

2026 Jan;45(2):278-294. PMID: 41326663
Oncogene

Targeting SREBP-dependent lipogenesis potentiates the anti-tumor activity of docetaxel by increasing membrane permeability and intracellular drug accumulation. [Abstract]

2025 Nov;44(45):4405-4412. PMID: 41046255
Int J Mol Med

Paeoniflorigenone inhibits ovarian cancer metastasis through targeting the MUC1/Wnt/β‑catenin pathway. [Abstract]

2024 Jul;54(1):60. PMID: 38785138
Arch Pharm Res

Modulating versatile pathways using a cleavable PEG shell and EGFR-targeted nanoparticles to deliver CRISPR-Cas9 and docetaxel for triple-negative breast cancer inhibition. [Abstract]

2024 Nov;47(10-11):829-853. PMID: 39482441
Biofabrication

3D bioprinting of multi-cellular tumor microenvironment for prostate cancer metastasis. [Abstract]

2023 Jun 9;15(3). PMID: 37236173
Cell Mol Gastroenterol Hepatol

Fibrinogen/AKT/Microfilament Axis Promotes Colitis by Enhancing Vascular Permeability. [Abstract]

2021;11(3):683-696. PMID: 33075564
Free Radic Biol Med

Targeted delivery of nebivolol via lactoferrin-modified liposomes inhibits NEK7-mediated pyroptosis to ameliorate inflammatory bowel disease. [Abstract]

2026 Aug 16:252:493-508. PMID: 42061481
Clin Transl Med

2026 Jul;16(7):e70737. PMID: 42415249
Cancer Immunol Res

Discovery of podofilox as a potent cGAMP-STING signaling enhancer with antitumor activity. [Abstract]

2023 May 3;11(5):583-599. PMID: 36921097
ACS Appl Mater Interfaces

Single-Cell Fluidic Force Spectroscopy Reveals Dynamic Mechanical Fingerprints of Malignancy in Breast Cancer. [Abstract]

2024 Sep 25;16(38):50147-50159. PMID: 39105773
ACS Appl Mater Interfaces

Glutathione and Esterase Dual-Responsive Smart Nano-drug Delivery System Capable of Breaking the Redox Balance for Enhanced Tumor Therapy. [Abstract]

2023 May 3;15(17):20697-20711. PMID: 37083309
Cell Rep

Elevating PLK1 overcomes BETi resistance in prostate cancer via triggering BRD4 phosphorylation-dependent degradation in mitosis. [Abstract]

2024 Jul 3;43(7):114431. PMID: 38968071
Br J Pharmacol

A vitamin D-based strategy overcomes chemoresistance in prostate cancer. [Abstract]

2024 Nov;181(21):4279-4293. PMID: 38982588
Cancer Cell Int

Organoids as a model system for researching human neuroendocrine tumor of the breast. [Abstract]

2024 Dec 27;24(1):433. PMID: 39731167
Cancer Cell Int

Activation of the PERK/eIF2α axis is a pivotal prerequisite of taxanes to cancer cell apoptosis and renders synergism to overcome paclitaxel resistance in breast cancer cells. [Abstract]

2024 Jul 17;24(1):249. PMID: 39020371
Drug Deliv Transl Res

Surface-engineered nanostructured lipid carrier systems for synergistic combination oncotherapy of non-small cell lung cancer. [Abstract]

2021 Oct;11(5):2030-2051. PMID: 33215254
J Agric Food Chem

Eurochevalierines A - I, Sesquiterpene Alkaloid Hybrids with Anti-Triple Negative Breast Cancer Activity from Penicillium sp. HZ-5. [Abstract]

2024 Jul 31;72(30):16801-16811. PMID: 39016690
Eur J Med Chem

Jatrophane diterpenoids from Euphorbia sororia as potent modulators against P-glycoprotein-based multidrug resistance. [Abstract]

2018 Feb 25:146:157-170. PMID: 29407947
Cell Biosci

Modulation of cell cycle increases CRISPR-mediated homology-directed DNA repair. [Abstract]

2023 Nov 25;13(1):215. PMID: 38007480
Biochem Pharmacol

Precision-engineered reporter cell lines reveal ABCG2 regulation in live lung cancer cells. [Abstract]

2020 May;175:113865. PMID: 32142727
Life Sci

A protective role of ECSIT in chemotherapy-induced intestinal mucositis by maintaining Lgr5+ intestinal stem cells and gut homeostasis. [Abstract]

2026 Mar 15:389:124236. PMID: 41611204
Life Sci

N6-methyladenosine-modified circQKI inhibits prostate cancer docetaxel-sensitivity via miR-188-3p/Beclin-1 pathway. [Abstract]

2025 Jul 1:372:123646. PMID: 40250752
Life Sci

Rational design, engineer, and characterization of a novel pegylated single isomer human arginase for arginine depriving anti-cancer treatment. [Abstract]

2021 Jan 1:264:118674. PMID: 33129876
Life Sci

Arctigenin inhibits proliferation of ER-positive breast cancer cells through cell cycle arrest mediated by GSK3-dependent cyclin D1 degradation. [Abstract]

2020 Sep 1:256:117983. PMID: 32565252
Breast Cancer Res

TMEM120B strengthens breast cancer cell stemness and accelerates chemotherapy resistance via β1-integrin/FAK-TAZ-mTOR signaling axis by binding to MYH9. [Abstract]

2024 Mar 19;26(1):48. PMID: 38504374
Oncogenesis

2026 Sep 28.
Oncogenesis

2026 Aug 20.
Int J Pharm

Surface-modified nanoparticles of docetaxel for chemotherapy of lung cancer: an intravenous to oral switch. [Abstract]

2023 Apr 5:636:122846. PMID: 36921744
Commun Biol

A compatible gravity-driven organoid perfusion (GDOP) platform for drug screening with sensitivity and toxicity process evaluation. [Abstract]

2026 Apr 2;9(1):718. PMID: 41922471
Cancer Immunol Immunother

Construction and application of a humanized mouse model for prostate cancer in immunotherapy. [Abstract]

2025 Nov 18;74(12):377. PMID: 41251708
Cell Rep Methods

RECOVER identifies synergistic drug combinations in vitro through sequential model optimization. [Abstract]

2023 Oct 23;3(10):100599. PMID: 37797618
Cancer Biol Ther

Suppression of LncRNA AC008406.3 sensitizes breast cancer cells to docetaxel via triggering cuproptosis. [Abstract]

2026 Dec 31;27(1):2676474. PMID: 42189063
Clin Epigenetics

Investigating the mechanisms by which low NAT1 expression in tumor cells contributes to chemo-resistance in colorectal cancer. [Abstract]

2025 May 6;17(1):77. PMID: 40329330
Pharmaceuticals (Basel)

Computational Modeling to Identify Drugs Targeting Metastatic Castration-Resistant Prostate Cancer Characterized by Heightened Glycolysis. [Abstract]

2024 Apr 29;17(5):569. PMID: 38794139
Int J Mol Sci

Dual Inhibition of BRAF-MAPK and STAT3 Signaling Pathways in Resveratrol-Suppressed Anaplastic Thyroid Cancer Cells with BRAF Mutations. [Abstract]

2022 Nov 19;23(22):14385. PMID: 36430869
Int J Mol Sci

Potent Anti-Cancer Properties of Phthalimide-Based Curcumin Derivatives on Prostate Tumor Cells. [Abstract]

2018 Dec 21;20(1):28. PMID: 30577600
Biol Direct

Integrative genomics unveils basement membrane-related diagnostic markers and therapeutic targets in esophageal squamous cell carcinoma. [Abstract]

2024 Sep 11;19(1):79. PMID: 39256753
J Enzyme Inhib Med Chem

Integrating virtual screening and molecular dynamics simulations to identify emodin as a PYCR1 inhibitor modulating docetaxel sensitivity in prostate cancer. [Abstract]

2026 Dec;41(1):2622725. PMID: 41665114
Microchem J

2025 Oct 15;218:115702.
ACS Omega

Identification of New Modulators and Inhibitors of Palmitoyl-Protein Thioesterase 1 for CLN1 Batten Disease and Cancer. [Abstract]

2024 Feb 28;9(10):11870-11882. PMID: 38496939
Chem Biol Interact

The prognostic gene CRABP2 affects drug sensitivity by regulating docetaxel-induced apoptosis in breast invasive carcinoma: A pan-cancer analysis. [Abstract]

2023 Mar 1:373:110372. PMID: 36736488
J Mol Med (Berl)

Tyrosine hydroxylase as a therapeutic target: insights from adrenergic nerve and TNBC cell interactions. [Abstract]

2026 Mar 19;104(1):53. PMID: 41857421
Mol Med Rep

miR‑133b affects cell proliferation, invasion and chemosensitivity in renal cell carcinoma by inhibiting the ERK signaling pathway. [Abstract]

2020 Jul;22(1):67-76. PMID: 32377748
Sci Rep

2026 Aug 29.
Sci Rep

Ring-finger protein RNF126 promotes prostate cancer progression via regulation of MBNL1. [Abstract]

2025 Jul 4;15(1):23847. PMID: 40615482
Int J Cancer

Establishment of patient-derived organoids for guiding personalized therapies in breast cancer patients. [Abstract]

2024 Jul 15;155(2):324-338. PMID: 38533706
Sci Rep

Monolayer culture alters EGFR inhibitor response through abrogation of microRNA-mediated feedback regulation. [Abstract]

2024 Mar 27;14(1):7303. PMID: 38538642
Cancer Sci

NOTCH3 promotes docetaxel resistance of prostate cancer cells through regulating TUBB3 and MAPK signaling pathway. [Abstract]

2024 Feb;115(2):412-426. PMID: 38115797
Transl Oncol

MiR-138-5p inhibits prostate cancer cell proliferation and chemoresistance by targeting APOBEC3B. [Abstract]

2023 Sep:35:101723. PMID: 37364333
Sci Rep

Investigation of enzalutamide, docetaxel, and cabazitaxel resistance in the castration resistant prostate cancer cell line C4 using genome-wide CRISPR/Cas9 screening. [Abstract]

2023 Jun 3;13(1):9043. PMID: 37270558
Eur J Med Res

Long non-coding RNA NORAD serves as a promoter of oncogenesis and inhibits ferroptosis via miR-144-3p-mTOR-ferritinophagy axis in cancer. [Abstract]

2025 Aug 4;30(1):704. PMID: 40760677
Cancers (Basel)

Dual Inhibitory Action of a Novel AKR1C3 Inhibitor on Both Full-Length AR and the Variant AR-V7 in Enzalutamide Resistant Metastatic Castration Resistant Prostate Cancer. [Abstract]

2020 Jul 28;12(8):2092. PMID: 32731472
J Cell Mol Med

Anticancer Activity of Annonacin and Its Synergistic Enhancement of Docetaxel Efficacy in Prostate Cancer. [Abstract]

2025 Dec;29(23):e70972. PMID: 41328625
J Pharm Investig

2025 Sep 19.
J Cell Mol Med

Telmisartan anti-cancer activities mechanism through targeting N-cadherin by mimicking ADH-1 function. [Abstract]

2022 Apr;26(8):2392-2403. PMID: 35224849
J Liposome Res

Fabrication, optimization, and in vitro evaluation of docetaxel-loaded nanostructured lipid carriers for improved anticancer activity. [Abstract]

2020 Jun;30(2):182-196. PMID: 31060404
Mol Oncol

Patient therapy outcome modeling in cancer organoids is improved by cancer-associated fibroblasts and organoid assembly convolution. [Abstract]

2026 Jun 5. PMID: 42246237
iScience

Identifying CTSF and GSTM3 as chemoresistance therapeutic targets in breast cancer through multi-omics MR analysis. [Abstract]

2025 Oct 30;28(12):113908. PMID: 41321627
iScience

ALKBH5-IGF2BP2 axis mediates prostate cancer progression and docetaxel resistance via m6A-stabilized CLSPN RNA. [Abstract]

2025 Sep 9;28(10):113520. PMID: 41069850
Biochim Biophys Acta Mol Cell Res

Cancer-associated fibroblasts secreting IL-6 inhibit the cisplatin and docetaxel killing effect in lung squamous cell carcinoma. [Abstract]

2025 Jul 31;1872(8):120029. PMID: 40752594
FEBS J

ABCB1-mediated docetaxel resistance reversed by erastin in prostate cancer. [Abstract]

2024 Jul;291(14):3249-3266. PMID: 38712529
Pharm Res

Active Targeting of Colorectal Cancer Using Chemotherapy-Loaded Nanoparticles Functionalized with a Folate Receptor-α (FRα) Ligand, Pemetrexed. [Abstract]

2025 Nov 18. PMID: 41254319
BJU Int

Drug-releasing intravesical floating technology for sequential gemcitabine and docetaxel in non-muscle-invasive bladder cancer. [Abstract]

2025 Nov 3. PMID: 41178321
BMC Cancer

Platycodin D-mediated METTL16 downregulation promotes docetaxel treatment of prostate cancer by regulating ferroptosis. [Abstract]

2025 Jul 1;25(1):1042. PMID: 40597047
Front Biosci (Landmark Ed)

Hypoxia-Induced VGF Promotes Cell Migration and Invasion in Prostate Cancer via the PI3K/Akt Axis. [Abstract]

2025 Feb 20;30(2):25522. PMID: 40018933
J Biol Chem

Androgen receptor splicing variant 7 (ARV7) inhibits docetaxel sensitivity by inactivating the spindle assembly checkpoint. [Abstract]

2021 Jan-Jun:296:100276. PMID: 33428943
PLoS Genet

Generation of prostate cancer assembloids modeling the patient-specific tumor microenvironment. [Abstract]

2025 Mar 31;21(3):e1011652. PMID: 40163511
Int J Med Sci

Integrative analysis identifies PIGK as an oncogenic glycosylphosphatidylinositol transamidase subunit with prognostic, immunological, and therapeutic relevance in head and neck cancer. [Abstract]

2026 Jan 1;23(1):161-176. PMID: 41399371
Pathol Res Pract

Alendronate-functionalized ZIF-8 nanoplatform for targeted delivery of SHH siRNA and docetaxel to treat prostate cancer bone metastasis. [Abstract]

2025 Sep:273:156138. PMID: 40694986
Breast Cancer

Quercetin Promote the Chemosensitivity in Organoids Derived from Patients with Breast Cancer. [Abstract]

2024 Dec 20:16:993-1004. PMID: 39720358
Materials

Antitumor Efficacy of Focused Ultrasound-MFL Nanoparticles Combination Therapy in Mouse Breast Cancer Xenografts. [Abstract]

2020 Mar 2;13(5):1099. PMID: 32121631
Micromachines

Integrated Experimental-Computational Framework for Drug Transport Quantification in 3D Microtissues™. [Abstract]

2026 Mar 9;17(3):332. PMID: 41900218
Mol Carcinog

ZNF480 Accelerates Chemotherapy Resistance in Breast Cancer by Competing With TRIM28 and Stabilizing LSD1 to Upregulate the AKT-GSK3β-Snail Pathway. [Abstract]

2025 Jan;64(1):192-208. PMID: 39503216
Arch Biochem Biophys

KIF14 mediates cabazitaxel-docetaxel cross-resistance in advanced prostate cancer by promoting AKT phosphorylation. [Abstract]

2023 Mar 15:737:109551. PMID: 36822388

Docetaxel Trihydrate purchased from MedChemExpress. Usage Cited in: Arch Biochem Biophys. 2023 Mar 15:737:109551. [Abstract]

Docetaxel (30 nM) exhibits anti-tumor activity in parental (DU145 and PC-3) and docetaxel-resistant (DU145/DTX50 and PC-3/DTX30) cell lines by down-regulating KIF14 expression.
Reprod Toxicol

Protective effects of rutin against docetaxel-induced testicular damage in rats: Effects on antioxidant defence, apoptosis and autophagy. [Abstract]

2026 Jan:139:109110. PMID: 41248718
Transl Lung Cancer Res

Construction of a lung cancer 3D culture model based on alginate/gelatin micro-beads for drug evaluation. [Abstract]

2024 Oct 31;13(10):2698-2712. PMID: 39507032
Front Oncol

Erastin Reverses ABCB1-Mediated Docetaxel Resistance in Ovarian Cancer. [Abstract]

2019 Dec 19:9:1398. PMID: 31921655
Chem Biol Drug Des

Polyphyllin VII Enhances the Sensitivity of Prostate Cancer Cells to Docetaxel by Promoting Mitochondrial Dysfunction and Inducing Ferroptosis. [Abstract]

2025 Feb;105(2):e70053. PMID: 39871642
Biochem Biophys Rep

Peroxiredoxin-1 as a molecular chaperone that regulates glutathione S-transferase P1 activity and drives mutidrug resistance in ovarian cancer cells. [Abstract]

2024 Jan 14:37:101639. PMID: 38288281
Breast Cancer Res Treat

Organoid models derived from patients with malignant phyllodes tumor of the breast. [Abstract]

2023 Jul;200(2):193-201. PMID: 37204665
J Cancer Res Clin Oncol

Docetaxel enhances the therapeutic efficacy of PSMA-specific CAR-T cells against prostate cancer models by suppressing MDSCs. [Abstract]

2022 Dec;148(12):3511-3520. PMID: 35962287
J Therm Biol

2026 Sep 28:141:104576. PMID: 42828942
J Appl Polym Sci

18 February 2022.
J Microencapsul

Fabrication, optimisation and in vitro evaluation of docetaxel and curcumin Co-loaded nanostructured lipid carriers for improved antitumor activity against non-small cell lung carcinoma. [Abstract]

2020 Dec;37(8):543-556. PMID: 32924677
J Microencapsul

Docetaxel-loaded PAMAM-based poly (γ-benzyl-l-glutamate)-b-d-α-tocopheryl polyethylene glycol 1000 succinate nanoparticles in human breast cancer and human cervical cancer therapy. [Abstract]

2019 Sep;36(6):552-565. PMID: 31403342
Pharm Dev Technol

Dual-modified PCL-PEG nanoparticles for improved targeting and therapeutic efficacy of docetaxel against colorectal cancer. [Abstract]

2021 Oct;26(8):910-921. PMID: 34280065
Int J Immunopathol Pharmacol

2026 Jan-Dec:40:3946320261474427. PMID: 42536653
PLoS One

RIPK2 induces docetaxel resistance in prostate cancer through the NF-κB/P-gp signaling pathway. [Abstract]

2026 Jan 21;21(1):e0341445. PMID: 41563982
Discov Oncol

Targeting XPO6 inhibits prostate cancer progression and enhances the suppressive efficacy of docetaxel. [Abstract]

2023 May 27;14(1):82. PMID: 37243787
Clin Transl Oncol

Establishment of an acquired lorlatinib-resistant cell line of non-small cell lung cancer and its mediated resistance mechanism. [Abstract]

2022 Nov;24(11):2231-2240. PMID: 35852680
Biochem Biophys Res Commun

2026 Sep 24:832:154364. PMID: 42542043
Biochem Biophys Res Commun

Vindoline, a vinca alkaloid derived from Catharanthus roseus, targets ABCB1 to overcome docetaxel resistance in prostate cancer. [Abstract]

2026 Jun 18:818:153767. PMID: 42000630
Oncol Lett

PP2A promotes apoptosis and facilitates docetaxel sensitivity via the PP2A/p-eIF4B/XIAP signaling pathway in prostate cancer. [Abstract]

2022 Mar;23(3):101. PMID: 35154432
Anticancer Drugs

Exosomal circRNA Scm-like with four malignant brain tumor domains 2 (circ-SFMBT2) enhances the docetaxel resistance of prostate cancer via the microRNA-136-5p/tribbles homolog 1 pathway. [Abstract]

2022 Oct 1;33(9):871-882. PMID: 36136987
Eur J Histochem

Docetaxel-resistant triple-negative breast cancer cell-derived exosomal lncRNA LINC00667 reduces the chemosensitivity of breast cancer cells to docetaxel via targeting miR-200b-3p/Bcl-2 axis. [Abstract]

2022 Oct 25;66(4). PMID: 36281649
Biomed Chromatogr

Investigation of the apoptosis-inducing effect of docetaxel by comprehensive LC-MS-based metabolomics and network pharmacology approaches. [Abstract]

2022 Sep;36(9):e5417. PMID: 35633112
Mol Biol Res Commun

Combinatorial effects of telmisartan and docetaxel on cell viability and metastatic gene expression in human prostate and breast cancer cells. [Abstract]

2022 Mar;11(1):11-20. PMID: 35463822
Int J Clin Exp Pathol

2017;10(3):3033-3042.
Adv Urol

2026 Apr 15;2026(1):7448726.
Biomed Pharmacother

2026 Sep:202:119803. PMID: 42537395
Preprints

2026 Mar 3.
bioRxiv

2026 Mar 27.
bioRxiv

2026 Mar 18.
bioRxiv

Loss of PIK3CA allows in vitro growth but not in vivo progression of KRAS mutant lung adenocarcinoma in a syngeneic orthotopic implantation model. [Abstract]

2026 Feb 4:2026.02.02.701385. PMID: 41676515
SSRN

2025 Dec 26.
Res Sq

2025 Sep 7.
bioRxiv

2025 Sep 21.
University of Granada

2025.
SSRN

2025 Jun 4.
bioRxiv

2025 June 01.
Res Sq

Novel mixed cancer-cell models designed to capture inter-patient tumor heterogeneity for accurate evaluation of drug combinations. [Abstract]

2025 May 16:rs.3.rs-6590535. PMID: 40470249
University of Granada

2025.
University of Beirut

2025.
bioRxiv

Diverse microtubule-destabilizing drugs induce equivalent molecular pathway responses in endothelial cells. [Abstract]

2025 Jan 24:2025.01.22.632572. PMID: 39896568
University of Minnesota

2024.
SSRN

2024 Mar 22.
bioRxiv

Inferring therapeutic vulnerability within tumors through integration of pan-cancer cell line and single-cell transcriptomic profiles. [Abstract]

2023 Nov 1:2023.10.29.564598. PMID: 37961545
Biomed Pharmacother

Dual receptor specific nanoparticles targeting EGFR and PD-L1 for enhanced delivery of docetaxel in cancer therapy. [Abstract]

2023 Sep:165:115023. PMID: 37329708
Preprints

2023 Jul 13.
Biomed Pharmacother

Patient-derived organoid culture of gastric cancer for disease modeling and drug sensitivity testing. [Abstract]

2023 Jul:163:114751. PMID: 37105073
University of Adelaide

2023 Jan.
Patent

US20230145200A1.
Research Square Print

November 29th, 2022.
Research Square Print

November 29th, 2022.
Oxid Med Cell Longev

Ferroptosis Induction Improves the Sensitivity of Docetaxel in Prostate Cancer. [Abstract]

2022 May 24:2022:4930643. PMID: 39282153
J Oncol

Solamargine Inhibits Prostate Cancer Cell Growth and Enhances the Therapeutic Efficacy of Docetaxel via Akt Signaling. [Abstract]

2022 Mar 10:2022:9055954. PMID: 35310915
Seoul National University

Molecular medicine and Biopharmaceutical sciences. 2021 Dec.
Mater Sci Eng C Mater Biol Appl

Reactive oxygen species and glutathione dual responsive nanoparticles for enhanced prostate cancer therapy. [Abstract]

2021 Apr:123:111956. PMID: 33812584
Research Square Preprint

2021 Jan.
Nanotheranostics

Resveratrol and its Nanoparticle suppress Doxorubicin/Docetaxel-resistant anaplastic Thyroid Cancer Cells in vitro and in vivo. [Abstract]

2021 Jan 1;5(2):143-154. PMID: 33457193
Nanotheranostics

Resveratrol and its Nanoparticle suppress Doxorubicin/Docetaxel-resistant anaplastic Thyroid Cancer Cells in vitro and in vivo. [Abstract]

2021 Jan 1;5(2):143-154. PMID: 33457193
Oncotarget

Molecular-genetic profiling and high-throughput in vitro drug screening in NUT midline carcinoma-an aggressive and fatal disease. [Abstract]

2017 Dec 2;8(68):112313-112329. PMID: 29348827
Oncotarget

Brachyury as a potential modulator of androgen receptor activity and a key player in therapy resistance in prostate cancer. [Abstract]

2016 May 17;7(20):28891-902. PMID: 27049720

Docetaxel Trihydrate purchased from MedChemExpress. Usage Cited in: Oncotarget. 2016 May 17;7(20):28891-902. [Abstract]

Western blot analyses for Brachyury and AR expression in prostate cell lines treated with Docetaxel (Doc) or with XRP6258 (Cab). Graphs represent the densimetric semi-quantification of western blot images.

Solvant et solubilité

In Vitro:

DMSO : 250 mg/mL (290.05 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Ethanol : 50 mg/mL (58.01 mM; Need ultrasonic)

H₂O : < 0.1 mg/mL (insoluble)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.1602 mL

5.8009 mL

11.6019 mL

5 mM

0.2320 mL

1.1602 mL

2.3204 mL

10 mM

0.1160 mL

0.5801 mL

1.1602 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% EtOH 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (2.90 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% EtOH 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (2.90 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% EtOH 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (2.90 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Protocol 4

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (2.41 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 5

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (2.41 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 6

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (2.41 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocole

All Cell Biology Animals and Diseases Signal Pathway Related

Detection of Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
Nephrotoxicity Study
This protocol assesses nephrotoxicity by combining functional kidney injury readouts, urinary/tissue injury biomarkers, and renal histopathology. Serum creatinine and BUN reflect impaired kidney function, while KIM-1, NGAL, clusterin, osteopontin, IL-18, cystatin C, nephrin, Oat5, urinary protein, glucose, and alkaline phosphatase have been used to detect tubular injury in cisplatin-, gentamicin-, and acetaminophen-induced nephrotoxicity models.
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
Mammalian live/dead viability and cytotoxicity staining
Live/dead viability and cytotoxicity staining assays are based on the simultaneous detection of intracellular esterase activity in metabolically active (viable) cells and membrane integrity loss in non-viable cells. In commonly used dual-staining approaches, membrane-permeant fluorogenic substrates are converted by intracellular esterases into fluorescent products in live cells, while impermeant DNA-binding dyes selectively enter cells with compromised plasma membranes and label nucleic acids in dead or dying cells, enabling discrimination between viable and non-viable populations by fluorescence microscopy or flow cytometry.
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
Hepatotoxicity Study
This protocol evaluates hepatotoxicity using complementary in vivo mouse APAP acute liver injury and in vitro hepatocyte-based cytotoxicity readouts. In vivo APAP injury is assessed by serum ALT/AST, liver histology, hepatic glutathione, protein adducts, necrosis, inflammation, and regeneration-related endpoints. In vitro hepatotoxicity is assessed by loss of viability, leakage of ALT/AST/LDH, oxidative-stress markers, mitochondrial function, nuclear morphology, intracellular calcium, and high-content imaging endpoints.
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (313 KB)
SDS (557 KB)
- English - EN (557 KB)
- Français - FR (557 KB)
- Deutsch - DE (557 KB)
- Norwegian - NO (557 KB)
- Español - ES (557 KB)
- Swedish - SV (557 KB)
- Italian - IT (557 KB)
- Korean - KR (557 KB)
- Portuguese - PT (557 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Dong X, et al. Maximum tolerated dose and toxicity evaluation of orally administered docetaxel granule in mice. Toxicology reports. 2024 Jun;12:430-435.

[2]. Pieniążek A, et al. Oxidative stress induced in rat liver by anticancer drugs doxorubicin, paclitaxel and docetaxel. Advances in medical sciences. 2013;58(1):104-11.

[3]. Marchettini P, et al. Docetaxel: pharmacokinetics and tissue levels after intraperitoneal and intravenous administration in a rat model. Cancer chemotherapy and pharmacology. 2002 Jun;49(6):499-503.

[4]. Clarke SJ, et al. Clinical pharmacokinetics of docetaxel. Clinical pharmacokinetics. 1999 Feb;36(2):99-114.

[5]. Hernández-Vargas H, et al. Molecular profiling of docetaxel cytotoxicity in breast cancer cells: uncoupling of aberrant mitosis and apoptosis. Oncogene. 2007 May 03;26(20):2902-13.

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
Ethanol / DMSO	1 mM	1.1602 mL	5.8009 mL	11.6019 mL	29.0047 mL
	5 mM	0.2320 mL	1.1602 mL	2.3204 mL	5.8009 mL
	10 mM	0.1160 mL	0.5801 mL	1.1602 mL	2.9005 mL
	15 mM	0.0773 mL	0.3867 mL	0.7735 mL	1.9336 mL
	20 mM	0.0580 mL	0.2900 mL	0.5801 mL	1.4502 mL
	25 mM	0.0464 mL	0.2320 mL	0.4641 mL	1.1602 mL
	30 mM	0.0387 mL	0.1934 mL	0.3867 mL	0.9668 mL
	40 mM	0.0290 mL	0.1450 mL	0.2900 mL	0.7251 mL
	50 mM	0.0232 mL	0.1160 mL	0.2320 mL	0.5801 mL
DMSO	60 mM	0.0193 mL	0.0967 mL	0.1934 mL	0.4834 mL
	80 mM	0.0145 mL	0.0725 mL	0.1450 mL	0.3626 mL
	100 mM	0.0116 mL	0.0580 mL	0.1160 mL	0.2900 mL

Bioz

Docetaxel Trihydrate

183 Cited Publications

100 mg Obtenir un devis

Subscribe to the

MedChemExpress

Newsletter

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

Docetaxel Trihydrate

Publications Citing Use of MedChemExpress (MCE) Docetaxel Trihydrate

Voir tous les produits spécifiques à Isoform Cytochrome P450